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Summary
Pre-eclampsia is a condition unique to pregnancy and primarily affects the maternal
and placental vascular endothelium. It has significant morbidity and mortality
consequences for both mother and infant. Despite global research into the aetiology
of the condition, the cause for this condition remains unknown. Several factors,
including a strong family history of hypertension in pregnancy point to a familial or
genetic component in the pathophysiology of this complication.
The purpose of this research project was to investigate candidate genes implicated in
endothelial damage. Common methylene-tetra-hydrofolate reductase (MTHFR) gene
mutations C677T and A1298C, factor V Leiden mutation R506Q and prothrombin
mutation A20210G were investigated in 50 patients with an uncomplicated pregnancy
outcome (controls) and 350 patients with various clinical manifestations of pre-
eclampsia, including severe, early onset forms and abruptio placentae. Fasting
homocystein levels were determined biochemically on all participants.
In addition, 126 consecutive pregnant patients were recruited at booking, fasting
lipograms were performed on them as well as mutation screening of 7 common
mutations in the low-density lipoprotein receptor gene. This was correlated with
eventual pregnancy outcome, and those with an uncomplicated outcome were
selected as an additional control group.
A significant association between hyperhomocysteinaemia and early onset severe
pre-eclampsia could be demonstrated. Mutant allele T of the C677T mutation could
be associated with hyperhomocysteinaemia but not with pre-eclampsia whilst mutant
allele C of mutation A1298C demonstrated a significant correlation with diastolic
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blood pressure. In addition, combined heterozygosity for these mutations may serve
as a marker for abruptio placentae.
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Opsomming in Afrikaans
Pre-eklampsie is 'n hipertensiewe toestand uniek aan menslike swangerskap en dit
affekteer hoofsaaklik die vaskulêre endoteel. Die toestand hou ernstige morbiditeit en
. mortaliteit vir beide ma en baba in en na jare se navorsing is die oorsaak van hierdie
toestand steeds onbekend. Epidemiologiese studies toon 'n duidelike familiële
verband aan wat die vermoede laat ontstaan dat daar 'n onderliggende genetiese
aspek tot die ontwikkeling van die siektetoestand is.
Die doel van hierdie navorsingsprojek was om gene te ondersoek wat geïmpliseer
word in endoteel skade. Twee algemene mutasies, C677T en A1298C in die MTHFR
geen asook faktor V Leiden R506Q en protrombien A20210G mutasies is ontleed in
50 pasiënte met 'n ongekompliseerde swangerskapsverloop en in 350 pasiënte met
'n swangerskap gekompliseer deur verskillende kliniese manifestasies van die
siekteproses, insluitende vroeë aankoms erge pre-eklampsie en abruptio placentae.
Op alle pasiënte is ook 'n vastende homosistiën vlak biochemies bepaal.
'n Verdere 126 opeenvolgende pasiënte is gewerf tydens hulle eerste besoek aan die
voorgeboortekliniek en vastende lipogramme is op almal uitgevoer. Mutasie sifting vir
7 algemene mutasies in die lae-digtheids lipoproteïen reseptor geen is op hierdie
groep gedoen en die resultaat is met die uiteindelike swangerskapsuitkoms
gekorreleer. Pasiënte met 'n uitkoms ongekompliseer deur hipertensie is gekies om
deel te wees van 'n verdere kontrolegroep.
Daar was 'n betekenisvolle verband tussen hiperhomositiënemie en erge, vroeë
aankoms pre-eklampsie. Die T alleel van die C677T mutasie is geassosieer met
hiperhomosistiënemie maar nie met pre-eklampsie nie. Die C alleel van die A 1298C
mutasie toon 'n betekenisvolle verband met diastoliese bloeddruk. Gekombineerde
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heterosigositeit vir beide MTHFR mutasies kan 'n moontlike merker vir abruptio
placentae wees.
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Chapter 1
1.1 Introduction
Pre-eclampsia is a condition unique to pregnancy and it primarily affects the maternal
and placental vascular endothelium. One of the main problems encountered with pre-
eclampsia is the definition of the condition. For the purpose of this thesis, pre-
eclampsia will be defined by the criteria for the International Society for Hypertension
in pregnancy [Davey and MacGillivray, 1988]. This includes a blood pressure of
140/90 mmHg measured on two occasions, at least four hours apart, arising for the
first time after 20 weeks of gestation, coupled with significant proteinuria (300 mg/I in
a 24-hour urine collection or 2+ on diagnostic urine sticks). All patients recruited for
the different studies in this project were identified according to these diagnostic
criteria.
Hypertension is central in the diagnostic criteria of most definitions but is considered
only part of the spectrum of the disease that may include intra-uterine growth
restriction (IUGR), platelet dysfunction, liver enzyme abnormalities, hemolysis and
systemic disturbances of the kidneys, clotting system and endothelial vasculature.
Pre-eclampsia is therefore a clinical syndrome recognised by its signs and not a
disease, and does not automatically leads to eclampsia, as the name implies.
The hypertensive conditions of pregnancy complicate 5-10% of all pregnancies
[Sibai, 1992]. World-wide, between 14% and 20% of primigravidae and 5.7% - 7.3%
of multigravidae will have pregnancies complicated by pre-eclampsia [Gabbe et ai,
1996]. The only known cure for the condition is delivery of the feto-placental unit.
The implication for the often pre-term infant is the complications of prematurity,
including neurological damage, respiratory distress syndrome and necrotising
enterocolitis. Derangement of multiple organ systems characterise the maternal
Stellenbosch University http://scholar.sun.ac.za
15
symptom complex, including renal failure, liver dysfunction, hepatic rupture,
thrombocytopenia, hemolysis, intracranial haemorrhage and diffuse intravascular
coagulation. The long-term implication for women with pre-eclampsia is an increased
death rate in later life due to ischaemic heart disease [Jonsdottir et ai, 1995].
In 1998, hypertension in pregnancy was responsible for 23.2% of direct maternal
deaths in South Africa [Moodley and Pattinson, 1998]. Hypertension is the direct
cause of 30% of perinatally related wastage at Tygerberg Hospital [Prins et ai, 1997]
and may indirectly contribute to a further 10-20% of perinatal deaths due to IUGR
and (iatrogenic) prematurity with induction of labour for worsening maternal disease
[Murphy and Stirrat, 1999]. The perplexing aetiology and pathophysiology of this
condition have made it one of the most researched conditions in obstetrics.
There are several theories proposed for the origin of pre-eclampsia. In all likelihood,
the common pathophysiological pathway for the development of pre-eclampsia is
endothelial cell dysfunction [Dekker et ai, 1995]. The classical pathological lesion
observed in the placental bed, described as 'acute atherosis', is a nectrotizing
arteriopathy consisting of fibrinoid necrosis, the accumulation of lipid-laden
macrophages in the decidua and a perivascular infiltrate in the spiral arteries [Sattar
and Greer, 1999]. These features are similar to that in arteriosclerotic changes in the
non-pregnant population. There is enough evidence from research on hyperlipidemic
and cardiovascular patients that elevated serum lipids are associated with endothelial
dysfunction [Goode et ai, 1995].
In normal pregnancy there is an 8-10 fold increase in prostacyclin production with a
less pronounced rise in the vasoconstrictory prostaglandin thromboxane [Wang et ai,
1991a]. There is an imbalance in this relationship in patients with pre-eclampsia, with
increased levels of thromboxane leading to platelet aggregation on the inner lining of
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the spiral arteries which induce fibrin formation. Another endothelium-derived
vasodilatory substance, nitric oxide, is probably more important than prostacyclin in
maintaining a low vascular tone in the feto-placental unit [Myatt et al, 1992].
A further independent factor for arteriosclerotic disease is hyperhomocysteinaemia.
The most common genetic defect that results in mild hyperhomocysteinaemia is a
single base-pair substitution in the methylenetetrahydrofolate reductase (MTHFR)
enzyme, resulting in decreased plasma folate and impaired homocystein
remethylation [Rozen, 1997]. The homocystein levels in women with pre-eclampsia
are significantly higher than in nulliparas without pre-eclampsia [Rajkovic et al, 1997].
Hyperhomocysteinaemia is also associated with placental infarctions, a finding
common in pre-eclampsia [Goddijn-Wessel et ai, 1996].
The presence of a hypercoagulable state in pre-eclampsia is suggested by an
increased incidence of heritable causes of thrombosis in pre-eclampsia. A mutation
(the Leiden mutation) in exon 10 of the Factor V gene (A1691G), which results in the
substitution of arginine with glycine, causes resistance to activated protein C, a
naturally occurring anti-clotting factor, by abolishing the site of protein C cleavage
[Bertina et al, 1994]. A G/A transition at position 20210 of the prothrombin gene is
also associated with an increased incidence of venous and arterial thrombosis. Both
of these mutations act as independent risk factors for pre-eclampsia in certain
(predominantly Caucasian) populations [Grandone et ai, 1999].
Epidemiological studies indicate a strong familial component to pre-eclampsia
[Chesley et al, 1961]. Genetic susceptibility to pre-eclampsia has been linked to
various chromosomal regions including 7q36 [Guo et al, 1999]. It is likely that there
are several different genetic factors associated with maternal susceptibility.
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The different factors implicated in the pathophysiology of pre-eclampsia will be
investigated in the following sections: 1.2 Genetic aspects of pre-eclampsia 1.3
Homocystein metabolism and mutation, 1.4 Thrombophilia and pre-eclampsia and
1.5 Lipoproteins and pre-eclampsia. Chapter 2 describes the materials and methods
used in the studies. The demographic characteristics of the patients involved in the
different studies performed are analysed in section 2.2. The results of the different
studies are presented in article format in chapter 3.
1.2 Genetic aspects of pre-eclampsia
The problem with collecting affected pedigrees in this disease is that pre-eclampsia
affects only women, and then usually only during their first pregnancy. Analysis of the
pattern of inheritance is difficult, as the only known marker of a possible defective
gene is the development of pre-eclampsia. Half of the population (men) is excluded
in any model, so are non-pregnant women and when pregnant, the disease only
manifests more than halfway through gestation. With a pregnancy involved, it is
difficult to determine whether the syndrome develops from the genotype of the fetus,
the mother or a combination of the two.
The susceptibility to pre-eclampsia is highly heritable. Chesley et al [1961] reported
the incidence of pre-eclampsia and eclampsia in daughters and sisters of patients
with eclampsia to be increased compared with the incidence in the local maternity
hospital. The same authors reported an eight-fold increased incidence of pre-
eclampsia in daughters of mothers with pre-eclampsia compared with the normal
population [Chesley, 1978]. They proposed that pre-eclampsia is caused by a single
recessive gene in the affected mother, based on data collected over 49 years
[Chesley and Cooper, 1986]. The authors followed 147 sisters, 248 daughters and 74
granddaughters of women who had eclampsia in pregnancy. As controls they used
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131 daughters-in-law of these same women. The speculation was that, if the
genotype of the fetus was responsible, then the incidence of pre-eclampsia would be
the same in all the cohorts, as the babies are all similarly related to the grandmother.
The diagnosis of pre-eclampsia was made in 26% of first viable pregnancies in the
daughters and in 6.1% of daughters-in-law. Pre-eclampsia was diagnosed in 16.2%
of viable first pregnancies in the granddaughters. The incidence of pre-eclampsia in
the sisters of women with eclampsia was 37%. When compared to the incidence of
pre-eclampsia in the general population (5-7%) this data clearly demonstrated strong
familial incidence. It also implicates susceptibility rather than a shared environment
[Morgan and Ward, 1999]. However, this single recessive gene model does not
explain the high incidence of pre-eclampsia in twin pregnancies and pregnancies
complicated by trophoblastic neoplasia.
Liston and Kilpatrick [1991] examined six possible genetic models for pre-eclampsia
with a hypothetical susceptibility gene, with a dominant allele (A) and a recessive
allele (a). These are:
1. A maternal recessive gene hypothesis (a,a).
2. A shared recessive gene hypothesis, where both the mother and fetus are (a,a).
3. A fetal recessive gene hypothesis, where only the fetus is (a,a).
4. The maternal dominant gene hypothesis (A,A or A,a).
5. A shared dominant gene hypothesis, where both mother and fetus must be (A,A)
or (A,a).
6. The fetal dominant gene hypothesis, where the fetus alone is of genotype (A,A)
or (A,a).
They then used a mathematical model to predict an expected proportion of affected
pregnancies and compared this with published observations of the proportions of
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affected pregnancies in three studies [Kilpatrick et ai, 1989; Cooper et ai, 1979;
Adams and finlayson, 1961] (Table I). They concluded that only the shared recessive
gene hypothesis fits all the data and that it is improbable that the other five are
correct [Liston and Kilpatrick, 1991].
Early reports demonstrated that pre-eclampsia may be weakly associated with the
HLA DR4 genotype [Simon et ai, 1988; Kilpatrick et ai, 1989]. However, family
studies with restriction fragment length polymorphisms did not show close linkage
between maternal susceptibility to pre-eclampsia and the HLA-DR4 region [Wilton et
ai, 1990]. More recently, HLA class II haplotypes DR4 and DQw2 were shown to be
associated with low birthweight and low placental weight in 30 pre-eclamptic women
[Omu et ai, 1998]. This association may represent a direct susceptibility factor.
Other possible candidate genes for pre-eclampsia are those associated with
hypertension. So far, no evidence for linkage has been demonstrated between pre-
eclampsia and renin, pronatriodilatin, the mineralocorticoid and glucocorticoid
receptors, the amiloride-sensitive sodium/potassium antiporter and the alpha-3 and
beta-1 sodium/potassium ATPase genes [Hayward et ai, 1992].
A genome-wide scan on 343 pre-eclampsia-affected patients and 239 unaffected
relatives showed a maternal susceptibility factor for pre-eclampsia on chromosome
2p13 [Amgrimsson et al, 1999]. This data are consistent with the chromosome 2
locus harbouring a highly penetrant variant which is not common in the general
population, but is responsible for the cases of pre-eclampsia with a strong familial
component.
The possible role of paternal genes in the pathophysiology of the condition is
reflected in the high incidence of pre-eclampsia (27%) in women with gestational
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trophoblastic neoplasia [Curry et ai, 1975]. This intriguing cancer is the result of an
abnormal fertilisation process, where an ovum is fertilised by a haploid sperm, which
then duplicates its own genetic material. The ovum nucleus is either absent or
inactivated. The karyotype of the tumour is usually 46,XX with the chromosomes
entirely of patemal origin [Kajii and Ohama, 1977].
Another observation is the linear decrease in the risk for pre-eclampsia with timing of
conception within the first year of sexual cohabitation with a male partner. With
pregnancy occurring within 4 months of exposure to the male genetic material
(sperm), the risk for pre-eclampsia is 40%, a risk which drops to 5% after 12 months
of cohabitation [Robillard et ai, 1994]. This suggests primipatemity rather than
primigravidity as a possible model to explain the high incidence of pre-eclampsia in
first pregnancies, especially teenage pregnancies, where pregnancy usually follows
rapidly on sexual exposure [Robillard et ai, 1999].
If a genetic-immunological model is supposed, it may help explain why the same
gene product (for example a recessive gene) could induce pre-eclampsia in the first
pregnancy and impose protection against the disease in the next pregnancy.
Stellenbosch University http://scholar.sun.ac.za
21
Table I
Expected proportion of affected pregnancies according to different
mathematical models
Kilpatrick et Cooper et al, Adams et al,
ai, 1989 1979 1961
Observed proportion affected (%) 11.1 18.2 13.8
Expected proportion for each model (%)
Maternal recessive gene 32.7 38.2 38.2
Shared recessive gene 11.2 18.3 18.3
Fetal recessive gene 5.2 10.1 10.1
Maternal dominant gene 27.0 30.3 30.3
Shared dominant gene 14.3 17.2 17.2
Fetal dominant gene 14.3 17.2 17.2
The correlation between the shared recessive gene model (shaded row) and the
actual proportion of the population affected as published in different studies.
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1.3 Homocystein metabolism, hyperhomocysteinaemia and placental
vasculopathy
The only source of homocystein in Man is that derived from methionine, an essential
sulphur-containing amino acid of animal origin. Levels of methionine are four times
higher in extra-embryonic coelomic fluid and twice as high in amniotic fluid as in
maternal serum during early pregnancy. There is a concomitant lower level of
homocystein in these fluids [Steegers-Theunissen et ai, 1997]. This suggests a role
for methionine metabolism in early pregnancy. Concentrations of homocystein in
maternal blood, umbilical vein and umbilical artery taken during parturition reveal a
descending gradient, suggesting the likely incorporation of homocystein into the fetal
metabolie cycle [Malinow et al, 1998].
Homocystein is metabolised via two pathways, namely re-methylation or trans-
sulphuration (Figure I). In the trans-sulphuration pathway, the sulphur atom of
homocystein is ultimately transferred to cysteine in a series of reactions. A pyridoxal-
5'-phosphate (Vitamin 86) dependent enzyme, cystathione-B synthetase, catalyses
homocystein to condense with serine to form cystathione. In cystathione-B
synthetase deficiency there is accumulation of homocystein and methionine in body
fluids with decreased concentrations of cysteine and cystine. Homocystein interferes
with normal cross-linking of collagen and plays an important role in the vascular
thrombotic complications that arise from this disease [Rosenberg, 1994].
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In the re-methylation pathway, a methyl group is added to homocystein to convert it
to methionine. The methyl group is derived from the conversion of 5-
methyltetrahydrofolate to tetrahydrofolate. This reaction is Vitamin 812 dependent
and requires the enzyme methionine synthetase. 5-Methyltetrahydrofolate is
synthesised enzymatically from 5,10-methylenetetrahydrofolate by another folate
cycle enzyme, 5,10-methylenetetrahydrofolate reductase (MTHFR). This MTHFR
enzyme is therefore critical for methionine synthesis and for tetrahydrofolate
generation. These reactions are essential for normal DNA and RNA function [Perry,
1999].
Hyperhomocysteinaemia can occur in two forms. The severe form, usually referred to
as homocysteinuria, is autosomal recessively inherited and results from deficiencies
in the cystathione-B synthetase or methylenetetrahydrofolate reductase (MTHFR)
enzymes. The mild form is a risk factor for vascular disease, but does not cause
overt disease [80ushey et al, 1995].
The severe forms of hyperhomocysteinaemia are rare, with only 10 children
diagnosed with the reductase deficiency by 1990 and about 50 cases described
world-wide. These deficiencies are too rare to account for more than a small
proportion of hyperhomocysteinaemic patients with cardiovascular disease
[Kluijtmans et ai, 1996]. A thermolabile variant of MTHFR was described in 1995
where a point mutation at nucleotide 677 is responsible for the thermolabile
phenotype [Frosst et ai, 1995]. Although defective, the enzyme is still functional. It
has decreased stability and is a plausible candidate for moderate
hyperhomocysteinaemia and arteriosclerotic disease.
The human MTHFR locus was mapped to chromosome 1p36.3 by in-situ
hybridisation [Goyette et al, 1994].With the single-strand conformation polymorphism
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method (SSCP) for mutation detection, a C to T substitution at basepair 677 was
identified. This resulted in the substitution of a valine for an alanine residue.
Homozygous mutant individuals have significantly higher plasma homocystein levels
[Ma et ai, 1996]. Plasma folate plays an important role in regulating homocystein in
these patients, and hyperhomocysteinaemia is observed primarily when the plasma
folate levels are lower [Jacques et ai, 1996].
Boushey and colleagues [1995] published a meta-analysis that summarised data on
homocystein levels in more than 4000 patients and several thousand individuals.
These data were calculated on fasting levels of homocystein alone. The relative risk
for persons with elevated homocystein for coronary artery disease was 1.7 (95% Cl
1.5-1.9); for cerebrovascular disease 2.5 (95% CI2.0-3.0) and for peripheral arterial
disease 6.8 (95% Cl 2.9-15.8). A large multicenter case-control study from 19
centres and 11 European countries, the European Concerted Action Project,
determined the risk factor of elevated plasma homocystein in vascular disease in a
prospective manner. They found that mild hyperhomocysteinaemia was an
independent risk factor for vascular disease, as was smoking, hypertension and
hypercholesterolaemia. Interestingly, there were synergistic interactions between
hyperhomocysteinaemia and hypertension and to a lesser effect with smoking,
indicating a potentiating effect if these factors were jointly present [Boers, 1997].
The mechanism by which homocystein promotes atherosclerosis is not well
understood. It may exert these effects through a direct action on the endothelium, on
clotting factors or on platelets. The platelet life span is normal in
hyperhomocysteinaemia. Platelet aggregation is normal and platelet morphology also
appears normal [Uhlemann et ai, 1976]. It does not appear that the vascular damage
is mediated by abnormal platelet function. In high concentrations, homocystein
impairs regulation of nitric oxide and other endothelial-derived vaso-active
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substances. It may also damage endothelial cells by the generation of free radicals
[Perry, 1999].
To investigate the direct effect of homocystein on the endothelium, Chambers and
colleagues [1999] studied the brachial artery diameter response with high-resolution
ultrasound in 17 healthy volunteers. They measured the response to hyperaemic flow
(endothelium dependent) and glyceryl trinitrate (endothelium independent) after
methionine and placebo administration. To investigate whether homocystein impairs
endothelial function through oxidative stress, they also studied pre-treatment with
Vitamin C before the methionine loading. They found that an acute elevation in
homocystein concentration is associated with a rapid (within 2 hours) onset of
endothelial dysfunction that can be prevented by pre-treatment with an anti-oxidant
like Vitamin C.
This also emphasises the importance of nutritional aspects in this condition. Folate
supplementation dramatically reduces the incidence of neural tube defects [Centers
for Disease Control 1992] and the MTHFR C677T polymorphism frequency is
increased two to three times in families of offspring with neural tube defects [Van der
Put et al, 1995]. With the relevance of folate, Vitamin B6 and B12 in the metabolic
pathways of homocystein, intervention studies with food fortification and vitamin
supplementation is necessary [Motulsky, 1996]. Interestingly, plasma concentrations
in pregnant women with a controlled (400-8001l9 daily) intake of folate are still
significantly lower than in non-pregnant controls; this may be a physiologic response
to pregnancy [Bonnette et ai, 1998].
Guttormsen and colleagues [1996] screened 18 043 healthy subjects for elevated
total plasma homocystein and identified 67 cases. Homozygosity for the C677T
mutation was found in 73.1% as opposed to 10.2% in a control group. In 37 patients
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intervention with low dose folate (0.2 mg/day) was started and within 7 weeks plasma
homocystein was reduced in 35 of them.
The long-term health impact of this type of intervention has not yet been addressed
so far [Bakker and Brandjes, 1997]. A pilot study on 14 patients with a positive
methionine-loading test (after a first pregnancy complicated by pre-eclampsia)
showed recurrent pre-eclampsia in 50% of them in the following pregnancy. They
were each treated with folate and Vitamin B6 in this pregnancy. The median
birthweight of the second pregnancy was 2867g compared with 1088 g in the first
pregnancy [Leeda et al, 1998].
There is a considerable population specificity in MTHFR locus allele frequencies.
Fletcher and Kessling [1998] summarised data from 37 studies published in the
English language up to 1998. The frequency of the C677T mutation in healthy
individuals varies from 16.3% in an Italian population, to 11% (Japanese), 5.4%
(Dutch) and was absent in Black Americans.
Homocystein levels are increased in a subset of women with severe pre-eclampsia.
Postpartum levels were measured as part of an investigation into underlying
disorders associated with severe early-onset pre-eclampsia [Dekker et ai, 1995]. A
positive methionine loading status was present in 17.7% of 79 patients tested.
Homocystein levels were also measured by Rajkovic and colleagues [1979] to
determine whether it is elevated in pregnancy complicated by pre-eclampsia. They
found plasma homocystein levels to be significantly higher in 20 nulligravid patients
with pre-eclampsia when compared with 20 healthy nulligravidas. However, folic acid
and vitamin B121evelswere not significantly different between the two groups.
Stellenbosch University http://scholar.sun.ac.za
28
Hyperhomocysteinaemia is also a risk factor for placental abruption and infarctions
[Goddijn-Wessel et al, 1996]. A study group of 84 women with prior placental
abruptio or infarctions were subjected to a methionine loading test in the non-
pregnant state; the incidence of abnormal homocystein concentration was 31%, in
contrast to 9% in a control group of patients with uncomplicated pregnancy (p <0.05).
A second mutation in the MTHFR gene (A1298C) was subsequently reported to
occur with a high carrier frequency in the general population [Weissberg et ai, 1998].
This mutation is also associated with decreased enzyme activity, but an isolated
mutation (heterozygous state) does not result in hyperhomocysteinaemia [Van der
Put et ai, 1998]. Combined heterozygosity for both C677T and A1298C mutations
does lead to hyperhomocysteinaemia [Van der Put et al, 1998] and may also be
associated with abruptio placentae [Gebhardt et ai, 2000]. The role of this and other
novel mutations in placental vasculopathy and other complications of pregnancy
remain to be elucidated.
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1.4Thrombophilia and pre-eclampsia
During normal pregnancy there are dramatic changes in the coagulation and
fibrinolytic systems. There is deposition of fibrin in the uteroplacental walls and
fibrinolysis is suppressed. There is an increase in the levels of clotting factors VII, VIII
and X and a doubling in the levels of fibrinogen. The end result is the well-described
hypercoagulability of pregnancy, protecting the mother against blood loss at delivery,
but also predisposing to thrombotic complications. Pulmonary embolism is the
leading cause of matemal deaths, alongside hypertensive disease, in developed
countries.
When a blood vessel is damaged, a complex interaction of clotting factors, the
coagulation cascade, is initiated by the activation of Factor XII by collagen and the
activation of Factor VII by thromboplastin release. The end result is the formation of
an insoluble fibrin clot from the soluble precursor fibrinogen. Thromboplastin, a
specific lipoprotein, occurs in large concentrations in the placenta. Protection against
generalised thrombosis is supplied by naturally-occurring anticoagulants, of which
antithrombin III and the protein C-thrombomodulin-protein S complex are the most
important. Protein C inactivates Factors Vand VIII in conjunction with its cofactors
protein Sand thrombomodulin. Abnormal forms of Factor V resist such inactivation
and can lead to thrombosis.
The association between placental infarcts and adverse pregnancy outcome,
especially midtrimester pregnancy loss and the development of pre-eclampsia, is well
described in the antiphospholipid syndrome. In this condition, anticardiolipin
antibodies are active against phospholipids in arterial and venous cell walls. The
higher the titre of the lupus anticoagulant and cardiolipin antibodies, the greater the
risk to the fetus [Branch et ai, 1985; 1988]. If one accepts this pathogenesis, a logical
hypothesis would be that other forms thrombophilia should also be associated with
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adverse pregnancy outcome [Nelson-Piercy, 1999]. The term thrombophilia refers to
acquired (antiphospholipid syndrome) or inherited abnormalities that alter the
haemostatic balance in favour of fibrin formation.
One such abnormality, described by Dahlback and colleagues in 1993, is activated
protein C resistance (APCR) Coagulation factor V acts as cofactor for activated
Factor X to activate prothrombin in the coagulation cascade. Factor V is inactivated
by cleavage by activated protein C. The human Factor V gene contains 25 exons that
range from 72 bp to 2820bp in length and spans more than 80 kb of genomic DNA
[Simioni, 1999]. Bertina and colleagues [1994] described a mutation in exon 10 of the
Factor V gene (A1691G) which results in the substitution of an arginine with a glycine
residue and abolishes the recognition site of protein C cleavage. This variant was
named the FV Leiden mutation, after the city in which it was discovered. In the United
States 5% of Caucasians and 1% of Blacks are heterozygous for this mutation
[Rouse et al, 1997].
The relationship between activated protein C resistance and adverse pregnancy
outcome was first reported in 1996. At a specialist recurrent miscarriage clinic, the
prevalence of APCR was significantly higher among women with a history of second-
trimester miscarriage (20%) when compared with a control group (4.3%; p<0.02)
[Rai et al, 1996]. In the same year results of the European Prospective Cohort on
Thrombophilia (EPCOT) were published [Preston et ai, 1996]. The study included
1384women; of 843 women with thrombophilia, 571 had 1524 pregnancies between
them. In the control group of 541 women, 395 had 1019 pregnancies. They studied
combined effects of FV Leiden mutation, antithrombin III deficiency and protein C and
S deficiencies. The highest odds ratio for stillbirth was in women with combined
defects (OR 14.3, 95% Cl 2.4-86). After adjustment for all possible confounding
Stellenbosch University http://scholar.sun.ac.za
31
factors, FV Leiden mutation was not recognised as a risk factor for miscarriage.
Unfortunately the incidence of hypertensive disease in this cohort was not reported.
The association between FV Leiden mutation and pre-eclampsia was first reported in
1995 in a small patient cohort with severe early-onset pre-eclampsia [Dekker et ai,
1995]. In a larger study of 158 women with severe pre-eclampsia, the incidence of
FV Leiden mutation was 8.9% and 4.2% in a control group (X2 4.686, p=0.03). All
patients were heterozygous for the mutation [Dizon-Townson et ai, 1996]. Since then,
several reports from different parts of the world confirmed or disputed this association
(Table II). The prevalence of the mutation in Africa is reported to be below 1% [Rees
et al, 1995].
In 1996, a guanine to adenine transition at position 20210 in the 3' untranslated
region of the prothrombin gene, was described [Poort et ai, 1996]. This mutation
(G20210A) was associated with elevated plasma prothrombin levels and an
increased risk of venous thrombosis. An independent association with pre-eclampsia
was reported in 1999 from Italy [Grandone et ai, 1999]. In 140 Caucasian patients
with pre-eclampsia, compared to 216 healthy normotensive women, the prothrombin
A20210G mutation was strongly associated with proteinuric hypertension (OR 3.31;
95% Cl 1.12-6.56). In 110 Israeli women (48 who are from the Ashkenazi ethnic
group) with serious pregnancy complications (abruptio placentae, severe pre-
eclampsia, IUGR) the incidence of the A20210G mutation in the prothrombin gene
was 10% compared to 3% in a control group (p<0.03) [Kupferminc et ai, 1999]. An
association with IUGR could not be established in a small study of 35 Caucasian
patients with IUGR [Wisotzkey et ai, 1999].
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Table II
Distribution of Factor V Leiden mutation world-wide
Countryl region Condition n Incidence Reference
Israel Recurrent fetal 39 48% Brenner et al,
loss 1997
Israel Poor obstetric 7 100% Rotmensch et
history al,1997
Hungary Severe pre- pregnant = 71 7% Nagy et al, 1998
eclampsia non-pregnant = 58 5.2%
pre-eclampsia = 69 18.8%
New South Wales Severe pre- pregnant = 150 0.07% Mimuro et al,
eclampsia pre-eclampsia = 50 8% 1998
HELLP 21 19% Krauss et al,
1998
pre-eclampsia 116 FV positive 25% Hastings et al,
women 1998
Italy pre-eclampsia controls = 4 1.8% Grandone et al,
pre-eclampsia = 11 7.9% 1999
East Anglia (UK) pre-eclampsia control = 200 5.3% O'Shaughnessy
pre-eclampsia = 283 5.5% et al, 1999
New York IUGR General population 7.9% Wisotzkey JD et
IUGR = 35 0% al,1999
Israel pre-eclampsia 110 20% Kupferminc et
al,1999
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1.5 Lipoproteins and pre-eclampsia
Fatty acids are an important precursor for prostaglandins and membrane lipids and
are also a critical source of metabolic energy. Unsaturated non-esterified fatty acids
(free fatty acids, FFA) are intrinsically toxic and have the ability to form free radicals.
During normal pregnancy, there are substantial changes in lipid metabolism. There is
a consistent increase in plasma triglycerides, cholesterol and phospholipids with
proportional enrichment of triglycerides in the lipoprotein fractions. Plasma
cholesterol concentration rises by approximately 25% and the triglyceride
concentration rises 2-3 fold [Potter et ai, 1979]. FFAs are mobilised from maternal
adipose tissue and this increased lipid transport supports growth and development of
the feto-placental unit. The greatest change occurs in the very low-density lipoprotein
(VLDL) triglycerides [Montelongo et al, 1992]. The main factor responsible for this
rise is an increased liver production of VLDL triglycerides and a decreased
elimination from the maternal circulation. The importance of these raised levels for
growth in the fetus is demonstrated by the marked abnormalities in fetal development
occurring in conditions with altered maternal lipid metabolism, such as overt diabetes
mellitus or hypothyroidism [Herrera et ai, 1997].
VLDL is composed of triglyceride (50%), phospholipid (18%), cholesterol ester
(16%), protein (7%) (which consists of approximately 50% Apo B, 45% Apo C and a
trace Apo A), cholesterol (6%) and FFA (3%) [Arbogast et ai, 1996]. The primary
function of VLDL is the transport of endogenous and dietary triglycerides, the major
source of stored energy. The abundance of VLDL triglycerides in the maternal
plasma may contribute to the accumulation of triglycerides in the low-density (LDL)
and high-density lipoproteins (HOL).
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In familial hypercholesterolaemia (FH), increased levels of LOL lead to accelerated
endothelial damage in the form of atherosclerosis. Endothelial cells line the vascular
system and modulate vascular tone by the secretion of modulating factors such as
prostacyclin and nitric oxide (vasodilatory) and thromboxane and endothelin
(vasoconstricting). Endothelial injury is an early event in pre-eclampsia. This is
demonstrated with fibronectin, a marker for endothelial cell damage, where elevated
levels are found long before clinical manifestation of pre-eclampsia in patients
destined to develop this condition [Gebhardt, 1998]. By similar analogy, the
increased levels of lipoproteins observed in pregnancy may cause endothelial
damage, precipitating the cascade of events that eventually lead to pre-eclampsia.
In rat models, aortic endothelial cell cultures show injury within one hour of exposure
to diabetic rat serum. The toxic component in the diabetic serum was identified as
VLDL [Arbogast and Taylor, 1996a]. The toxic activity of VLOL occurred in the
presence of all other serum components and the toxicity of the serum disappeared
with the removal of VLOL. In vitro serum toxicity of VLOL was also shown during
pregnancy in rats. This toxicity increased throughout gestation and disappeared after
birth [Chan and Pollard, 1978]. All the toxicity is associated with the triglyceride
subfraction rather than with the lipoprotein fractions. Other components carried by
VLOL (prostaglandin F2Cl, 17p-estradiol, progesterone, 25 hydroxycholesterol,
monopalmitolein, elaidyl alcohol, a-linolenyl alcohol or free fatty acids) were tested
for toxicity, but the toxicity appeared to be due to the VLOL fraction itself [Chan and
Pollard, 1981].
With these results, it was hypothesised that hypertriglyceridaemic human serum
might also be toxic to endothelial cells in vitro. However, this was not observed
[Arbogast, 1988]. Instead, a factor present in human sera masked this toxicity. This
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factor, named toxicity-preventing factor, was identified as human plasma albumin at
isoelectric point (pi) 5.6 [Arbogast and Taylor, 1996b]. The other major isoelectric
form of human plasma albumin is isoelectric point 4.8. The pi 4.8 form contains more
FFA and conversion from pi 4.8 to pi 5.6 suggests a loss of FFA. The pi 4.8 form is
responsible for transport of most of the FFA and remains constant throughout
pregnancy. The levels of the toxicity-preventing factor, plasma albumin pi 5.6,
decreases throughout normal pregnancy and eventually a point must be reached
where the toxicity of VLOL is expressed.
Pre-eclampsia is characterised by endothelial damage, leading to permeability of the
vascular endothelium, with leakage of plasma proteins, including albumin, to the
tissue. This results in the oedema commonly observed. With protracted loss of fluid
in the third space, matemal ascitis and pulmonary oedema develop. An increased
VLOL and lower toxicity-preventing factor early in pregnancy correctly identified
patients who subsequently developed pre-eclampsia [Arbogast et ai, 1996].
A lower level of albumin early in pregnancy can be due to nutritional deficiencies. It
may also be that a genetic susceptibility to endothelial damage in the form of
hypercholesterolaemia predisposes to the development of this disease. The
concentration of free fatty acids is elevated months before the development of pre-
eclampsia [Lorentzen et ai, 1995]. There is also a significant association between
first trimester total serum cholesterol and the risk of pre-eclampsia. Van den Elzen
and colleagues [1996] measured serum total cholesterol and HOL in 393 women
over the age of 36 years in the first trimester of pregnancy. Serial levels were
determined throughout pregnancy and correlated with the eventual outcome. They
found that the risk for pre-eclampsia increased 2.2 fold for every 1 mmol rise in
baseline serum cholesterol (95% Confidence Interval 1.2-4.2). The relative risk for
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pre-eclampsia exceeded 5 with a serum total cholesterol above 6 mmoiII when
compared to a level below 5 mmoiII (RR = 5.2; 95% Cl 1.2 - 22.5).
Postmenopausal women with a history of recurrent hypertension during their
pregnancies have significantly increased diastolic blood pressure and atherogenic
profiles when compared to matched controls without a prior history of hypertension in
pregnancy [Hubel et ai, 2000]. Also, the risk of dying from ischemic heart disease in
later life is increased in women who had hypertensive disease in pregnancy (RR
2.61, 95% Cl 1.11- 6.12) [Jonsdottir et ai, 1995]. It is likely that a combination of
genetic predisposition and environmental factors for atherosclerosis in later life is
unmasked earlier in life, by pregnancy, as pre-eclampsia. Further evidence for this
potential metabolic syndrome is an elevated body mass index (BMI; kg/m2) in women
with pre-eclampsia, regardless of parity, before, during and after pregnancy;
compared with women with normotensive pregnancies [Barden et ai, 1999].
There is very little information available on the reason for the exaggerated response
of plasma lipids during and preceding pre-eclampsia. There is a spectrum of
mutations identified in the promoter and coding region of the low density lipoprotein
receptor (LDLR) gene associated with FH [Day et al, 1997; Varret et al, 1998],
incorporated in two databases, http://www.ucl.ac.uklfh and http://www.umd.necker.frl.
This disease is common in the South African population and three founder mutations
in the LDLR gene account for 90% of the FH cases in the Afrikaner group {Kotze et
ai, 1989; Leitersdorf et ai, 1989]. These mutations also contribute to the
hypercholesterolaemia phenotype in the indigenous South African population of
mixed ancestry [Loubser et al, 1999],which has a high incidence of pre-eclampsia as
well. African women are also particularly prone to hyperlipidaemia during normal
pregnancy [Ahaneku et al, 1999].
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Apart from these three mutations, four other are of particular interest in the study
population. A six basepair deletion in exon 2 of the LOLR gene predominates in
Africans with familial hypercholesterolaemia [Thiart et ai, 2000]. A recently described
-175Grr variant in the footprinting 2 (FP2) cis-acting regulatory element of the LOLR
gene may play an important role in hypertension by virtue of a possible effect on
calcium metabolism [Scholtz et at, submitted]. Two other common mutations in exon
4, a 3 bp deletion (651 del GGT) [Meiner et ai, 1991] and an A to G substitution at
position 662 (0200G) can also be detected using the same primer set as for the
other mutations in exon 4 [Hobbs et ai, 1992]. The role of these seven mutations has
not been examined in the pathophysiology of pre-eclampsia.
Another lipoprotein subfraction that increases significantly in pre-eclampsia is small,
dense low-density lipoprotein (LOL-III) [Sattar et ai, 1997]. These small LOL
subfractions are more atherogenic than larger LOL species [Witzum, 1993]. They are
also more susceptible to oxidation [Wang et al, 1991a] and oxidised LOL inhibits
prostacyclin and nitric oxide synthesis [Chin et ai, 1992]. The result is platelet
activation, thromboxane release and vasospasm.
If increased levels of lipoprotein fractions contribute to the pathogenesis of pre-
eclampsia through direct endothelial damage, resolution of the disease post-partum
should be accompanied by a decrease in lipoprotein fractions. This was investigated
by Hubel et al in 1996. They collected venous blood samples pre-delivery and 24
hours and 48 hours post-delivery in eight women with pre-eclampsia and in nine
healthy pregnant patients. Circulating triglycerides and FFAs were dramatically
elevated in the pre-eclampsia group and this decreased within 48 hours post partum.
Apolipoprotein E (apoE) plays an important part in lipid metabolism and an increased
frequency of the 82 allele has been reported in women with severe pre-eclampsia
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[Nagy et ai, 1998;Williams et ai, 1996]. In a South African study involving a Western
Cape population group of mainly Black and Coloured patients, an increased
frequency of the &2allele was found in the pre-eclampsia group (19.9%) as well as in
the control group (19%) [Burton et ai, submitted]. In this population the &2allele is not
a risk factor for pre-eclampsia, but the high frequency thereof in the general
population may have cardiovascular implications in later life.
1.6 Hypothesis
The hypertensive conditions of pregnancy constitute a major social health issue and
exert a huge strain on the already-stressed health budget of the country. The clinical
presentation is highly variable due to the multi-systemic nature of the condition. After
more than a hundred years of dedicated research, no definite underlying cause for
the condition has been identified. Most research is currently directed towards the
management of the condition once it is diagnosed, with different conservative
management options involving anti-hypertensive or other drugs. A careful balance
must be maintained between early delivery, with its implications for fetal mortality and
morbidity, and conservative management with its possible adverse complications for
the mother.
Other areas of extensive research has included investigation of fluctuations in
various markers for endothelial damage and in possible preventative measures with
aspirin and other drugs which exert their influence on the endothelium.
DNA technology has advanced at a rapid pace and the entire human genome has
recently been sequenced. The tools are now available to dissect pre-eclampsia on a
molecular level. In most complex, multifactorial diseases like multiple sclerosis,
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ischemic heart disease or diabetes mellitus, there are complex gene-gene
interactions and interaction between genes and environmental factors present.
In this study, an approach was adopted in an attempt to understand the
pathophysiology of pre-eclampsia. The aim was to investigate candidate genes
implicated in endothelial vascular damage:
• To elucidate the role of mutations C677T and A1298C in the MTHFR gene in pre-
eclampsia and abruptio placentae.
• To confirm or dispute a previous finding of combined heterozygosity for these
mutations as a possible marker for abruptio placentae.
• To determine the contribution of inherited thrombophilia (the prothrombin
mutation A20210G and the factor V Leiden mutation) in the development of pre-
eclampsia and abruptio placentae
• To determine whether there is a correlation between mutations in the MTHFR
gene and clinical significant hyperhomocysteinaemia in the South African
population
• To investigate the role of hyperhomocysteinaemia in the pathophysiology of
placental vasculopathy
• To investigate the possible genetic contribution of mutations in the low-density
lipoprotein receptor in the development of pre-eclampsia. The hypothesis in this
regard is that common mutations in the LDLR gene associated with
hypercholesterolaemia also predispose to the development of pre-eclampsia.
Once the genetic aspect of pre-eclampsia is unravelled it may help to make
informative conclusions on pre-conceptual supplementation with folic acid and
various combinations of vitamins in the prevention or postponement of pre-
eclampsia.
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Chapter 2
Materials and methods
2.1 Patient selection
The study population consists of several groups and two control groups. The first
group (Group A) consists of 50 multigravidae that had pregnancies uncomplicated by
any of the hypertensive conditions (in the index pregnancy or any previous
pregnancy). They were selected after delivery at term from consecutive
uncomplicated pregnancies in the labour ward at Tygerberg Hospital. Patients with
infants with a birth weight below the tenth centile for gestation were excluded to
prevent inclusion of a possible case of intra-uterine growth restriction. The second
control group (Group L) (n=126) were selected at their first antenatal visit to
Tygerberg Hospital to represent the hospital population and they were followed
prospectively. This selection was done in 3 months, including all consecutive new
patients. At booking, fasting lipograms were performed on these patients for the lipid
evaluation part of the study.
The study groups were selected as follows:
B. Study group of 50 primigravidaewith onset of pre-eclampsia before 34 weeks.
C. Study group of 50 primigravidaewith onset of pre-eclampsia after 34 weeks.
D. Study group of 50 multigravidaewith severe pre-eclampsia before 34 weeks.
E. Study group of 50 multigravidaewith onset of pre-eclampsia after 34 weeks.
F. Study group of 50 primigravidaewith pregnancy-induced hypertension.
G. Study group of 50 multigravidaewith pregnancy-induced hypertension.
H. Study group of 50 patients who developed abruptio placentae during the
pregnancy, regardless whether it was accompanied by pre-eclampsia or not.
Stellenbosch University http://scholar.sun.ac.za
41
Hypertension and pre-eclampsia are defined according to the guidelines of the
International Society for the Study of Hypertension in Pregnancy (see 1.1,
introduction). Abruptio placentae is defined as an abnormal early detachment of the
placenta, followed by intra-uterine or vaginal bleeding. This is deemed significant
when more than 15%of the placenta is covered by a blood clot following delivery.
This is a non-experimental cohort-analytical study that ran over a 2-year period.
Informed consent was obtained from all patients using a specially designed form
approved by the Ethics Committee of the University of Stellenbosch (Appendix). The
project, including all ethical aspects, was approved by the Ethics Committee on 8
March 1999 (project number 99/025).
2.2 Demographic characteristics
The demographic characteristics of the patients in the different groups are shown in
Table III. Information on the taking of folate and iron supplementation was obtained
from each patient and verified from the antenatal charts. More than 83% of patients
in all the groups were taking prophylactic supplements.
The racial distribution for the 4059 deliveries at Tygerberg Hospital in 1999 was as
follows:
• Coloured (MixedAncestry Group) 3362 (82.8%)
• Black636 (15.6%)
• Caucasian 61 (1.6%)
The racial distribution between the groups is shown in Figure II. There were
significantly more Black patients with early onset severe pre-eclampsia
(primigravidae: p = 0.0033; multigravidae: p = 0.0315).
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Forty percent of patients in the control group admitted to smoking at any time during
their pregnancy. There is a significant lower incidence of smokers in all the
hypertensive groups (groups B-G), confirming published studies on the puzzling
apparent protective effect of cigarette smoking against the development of pre-
eclampsia [Zhang et ai, 1999]. There were significantly more smokers in the abruptio
group (p = 0.0012) than in the hypertensive groups combined (Figure III).
There was a strong history of hypertension in pregnancy in the mothers of daughters
admitted to the project in all the groups except the control group (Figure IV) and the
abruptio group. The numbers are too small to make any significant epidemiological
conclusion, but it is conspicuous that abruptio placentae does not seem to have an
apparently strong genetic link.
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Table III Demographic characteristics
A B C 0 E F G H I
(n=50) _(n=55) (n=50) (n=56) (n=51) (n=50) (n=53) (n=50)
Age 29 21 19.5 30 29 22 32 28
(18-43) (14-37) (15-37) (18-42) (17-46) (14-37) (20-43) (16-42)
Avs B* AvsC* B vs 0* Cvs E* Avs F*
Gravidity 3 1 1 3 2 1 3 2
(2-8) (2-7) .(2-81 (2-6) (1-6)
Parity 2 0 0 2 1 0 2 1
(1-7) .(0-6) (0-5) (0-5) (0-5)
Race: (%) 10% 36% 26% 29% 20% 14% 28% 20%
Black
Race: (%) Coloured 90% 64% 74% 71% 80% 86% 72% 80%
Avs B* Avs 0* AvsG*
Blood pressure: systolic 120 160 160 160 160 140 140 140
(100-140) (130-220) (130-200) (120-220) (130-260) (120-90) (120-210) (80-200)
Avs B* AvsC* Avs 0* Avs E* Avs F* AvsG* Avs H* .
Blood pressure: 80 105 110 110 108 100 100 90
diastolic (60-90) (80-150) (90-140) (90-160) (90-160) (90-120) (90-130) (60-130)
Avs B* AvsC* Avs 0* Avs E* Avs F* AvsG* Avs H*
Smoking (%) 40% 20% 20% 16% 20% 28% 20.8% 38%
Avs B* AvsC* Avs 0* Avs E* AvsG*
Iron supplementation 100% 86% 86% 83% 94% 98% 94% 90%
(%)
Folic acid (%) 100% 86% 86% 83% 94% 98% 94% 90%
Gestational age at - 29 36 29 36 38 36 33
diagnosis (19-33) (34-42) (20-37) (34-44) (21-42) (21-41 ) (24-40)
FvsG*
Gestational age at 39 30 36 31 36 39 38 33
delivery (37-44) (20-39) (34-42) (24-38) (31-44) (28-42) (26-42) (27-40)
Avs B* Avs C* Avs 0* Avs E* Avs F* AvsG* Avs H*
Birth weight 3256 1314 2603 (1358- 1218 2678 3044 2972 1751
(2460-4576) (592-2964) 4052) (1218-3430) (1314-4498) (910-4060) (768-4796) (762-3702)
-- -
Avs B* Avs C* Avs 0* Avs E* Avs F* AvsG* Avs H*
-
All values are given in the median, unless otherwise stated. The range is given in parenthesis.
·Statistically significant difference between groups as indicated at p< 0.05
A Control group
B Primigravidae < 34 weeks
C Primigravidae> 34 weeks
o Multigravidae < 34 weeks
E Multigravidae >34 weeks
F Primigravidae with PIH
G Multigravidae with PIH
H Abruptio group
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Figure II
Racial distribution of the different groups
90------------------~
80
70
60
50
40
30
20
10
o
Mixed
ancestry
Black
PG Primigravida
MG Multigravida
PIH Pregnancy-induced hypertension
.1999: All deliveries
E1Control
• PG <34 weeks
EIPG >34 weeks
EIMG <34 weeks
~ MG >34 weeks
EIPIH <34 weeks
D PIH >34 weeks
DAbruptio
Stellenbosch University http://scholar.sun.ac.za
45
Figure III
Smoking during pregnancy: control group vs. abruptio group and hypertensive
groups (B-G) combined
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Figure IV
History of hypertension during pregnancy (mothers vs. daughters)
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There is a significant relationship of hypertension in pregnancy between mothers and
their daughters. Only 2% of patients with an uncomplicated pregnancy outcome had
mothers with hypertension during their (the mothers') pregnancies.
(p = 0.0029)
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2.3 Collection of plasma for homocystein determination
Homocystein is synthesised by erythrocytes and leukocytes and production
continues after collection of blood. This production is minimised by storing samples
on ice. A protein rich meal within 8 hours of sampling can also affect blood levels of
homocystein. After separation of plasma, homocystein levels are stable and can
remain so for years when frozen at-200C or less [Perry, 1999].
For this study, blood for homocystein determination was always collected after an
overnight fast. An EDTA and clotted blood sample were obtained for plasma and
serum samples respectively and were stored on ice until centrifuged. The centrifuged
plasma was immediately frozen at -78°C until dispatched for analysis. A methionine-
loading test was traditionally used to detect heterozygosity for deficiency in the
cystathione-B synthetase enzyme. This test maybe a valuable adjunct as fasting
values sometimes fail to identify a patient at risk for vascular complications [Cattaneo
et ai, 1996]. A method to measure total homocystein in blood was introduced in the
late 1980s; this method determines the free homocystein fraction as well as the
protein-bound homocystein, making loading tests unnecessary [Ueland et ai, 1992].
For the purpose of this study, hyperhomocysteinaemia resulting from defects in the
MTHFR enzyme were deemed more important. Also, the safety of methionine
loading in pregnancy and the puerperium is not established as a sudden increase in
homocystein can precipitate a vascular crisis like abruptio placentae. Elevated fasting
levels constitute an equally strong excessive risk for arteriosclerotic disease as
elevated postload concentrations [Boers, 1997]. Homocystein levels were determined
at Pretoria University using the method described by Ubbink and co-workers in 1991.
The fasting serum samples were stored for lipogram and vitamin B12 and folate
analysis.
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2.4 Collection of blood for DNA extraction
Maternal blood for DNA extraction was obtained from a clean vein puncture in the
cubital fossa after informed consent was given. Two samples of 5 ml each in a tube
containing EDTA (1/10 volume 0.5M sodium EDTA) were frozen; one sample in a
conventional freezer until DNA extraction could be performed and the other sample
at -78°C as a back-up. When the paternal genetic contributor (male partner)
consented, a blood sample was obtained in a similar manner. Fetal blood was
obtained after delivery of the fetus and before delivery of the placenta. Taking care
not to contaminate the sample with maternal genetic material, two samples of 5 ml
each were obtained directly from the umbilical cord on the placental side, in EDTA,
and manipulated the same way as the maternal blood. If no blood was obtained at
the time of delivery of a live baby, a few drops of blood were taken from a heel prick.
In cases of intra-uterine death, blood was obtained after delivery from the fetus by
direct cardiac puncture.
2.5 DNA Extraction
DNA extraction was performed using an adaptation of the original salting out
procedure originally described by Miller et al [1988]. EDTA stored blood (5 ml) was
mixed with 50 ml cold lysis buffer (Appendix) in a polypropylene tube to produce lysis
of red cells. The sample was shaken periodically and placed on ice to enhance lysis.
Following destruction of red cells, the mixture was centrifuged at 1500 rpm for 10
minutes at room temperature. The supernatant was discarded without disturbing the
centrifuged pellet.
Fetal haemoglobin (HgbF) is composed of two a.-chains (identical to adult
haemoglobin, HgbA) and two y chains instead of the B-chains of HgbA. This
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difference amounts to 39 of the 149 amino acid residues in the haemoglobin
tetramere and results in a higher oxygen affinity of HgbF [Bissonnette, 1996]. It also
makes HgbF relatively more resistant to denaturation by alkali. This is the basis of
the Apt test, where easy denaturation of a blood sample of antepartum vaginal
bleeding with sodium hydroxide discloses its maternal origin. To extract fetal DNA,
the lysis buffer step was repeated until obvious lysis of red cells could be observed.
The pellet was then carefully washed with phosphate-buffered saline (PBS) and spun
down again at 1500 rpm for 10 minutes. The ceillysates were incubated overnight at
55°C with 3 ml nucleic lysis buffer (Appendix), 30 f.llproteinase K (10 mg/ml) and 300
ul 10% SOS. Subsequently, 1 ml of saturated 6M sodium chloride solution was
added and the sample shaken vigorously. It was then centrifuged at 2500 rpm for 15
minutes.
The DNA-containing supernatant was carefully decanted into a clean polypropylene
tube and 20-30 ml of ice-cold absolute ethanol was added to precipitate the DNA.
The DNA strands were carefully lifted from the solution with a plastic pipette and
sprayed with 70% ethanol to remove excess salt. The sample was then carefully
blotted against sterile blotting paper to remove excess fluid and transferred to a
labelled micro-centrifuge tube, where it was left at room temperature to airdry.
Approximately 600 f.ll of sterile distilled water was added to dissolve the pellet and
the mixture placed on a shaker for a few hours before storage at 4°C.
2.5..1 Cleaning of contaminated samples
DNA samples contaminated by protein or other impurities, especially fetal DNA
samples, were purified in the following manner. From the contaminated sample, 200
f.llwas placed in a clean polypropylene tube that was clearly labelled. To this, 200 f.ll
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of phenol chloroform (a mixture of phenol:chloroform:absolute ethanol 25:24:1) was
added. The solution was mixed thoroughly on a vortex and then centrifuged at 1500
rpm.
The aqueous layer (more or less 180 JlI) was gently removed with a pipette and
placed in a new clean, labelled polypropylene tube. An equal volume (180 Ill) of
chloroform and isoamyl alcohol (24:1 mixture) was added and the solution again
vortexed and centrifuged. The aqueous layer (180 JlI)was removed and placed in a
labelled, clean polypropylene tube. To this, 20 III of 3M sodium acetate was added
and mixed well. Two volumes of cold, absolute ethanol were added to precipitate the
DNA. The solution was then centrifuged for 30 seconds and the fluid carefully
discarded to retain the DNA-containing pellet. The pellet was washed with 70%
ethanol, centrifuged again and the resulting pellet was left at room temperature to
airdry, after which it was dissolved in 200 III of sterile water for use in PCR reactions.
2.6 peR
2.6.1 Factor V Leiden and Prothrombin mutations
A multiplex allele-specific amplification polymerase chain reaction (ASA-PCR) was
performed using primers described by Hezard et al (1998). Allele specific
oligonucleotides were synthesised to anneal directly to the wild-type and mutated
sequences respectively. In an individual homozygous for the mutation annealing will
only occur with the allele specific probe containing the mutation; in a heterozygous
individual annealing will occur with both the mutated and the wild-type probe (see
Figure XIV).
The mutation in the prothrombin gene was detected with the reverse primer (wild-
type allele) 5' cactgggagcattgaggatc 3', the mutated allele 5' cactgggagcattgaggatt 3'
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and the forward (consensus) primer 5' tctagaaacagttgcctggc 3'. This part of the
reaction yielded a DNA fragment of 340bp. For the Factor V Leiden mutation, the
forward primer (wild-type allele) was 5' cagatccctggacagacg 3', the mutated allele 5'
cagatccctggacagaca 3', and the consensus primer (reverse) 5' tgttatcacactggtgcttaa
3'. This yielded a 174bp DNA fragment. Polymerase chain reaction (PCR)
amplification was carried out in a 50 JlIreaction volume with 1 JlIof genomic DNA, 1
JlI (10pmolll) of each primer, 5JlI (5mM) of each of the four deoxynucleotide
triphosphates and 1JlIof Taq polymerase (5U1JlI).
Thermal cycling was performed at 95°C for 1 minute, followed by 30 cycles of 95°C,
1 minute; 56°C, 1 minute; 72°C, 1 minute followed by a final extension step of 72°C,
5 minutes. PCR products were resolved on a 1% Agarose gel, stained with ethidium
bromide and visualised under ultraviolet light (A26o nm).
2.6.2 MTHFR C677T mutation
Genotyping was performed by PCR amplification and Hinf I digestion as originally
described by Frosst et al [1995]. The primers used were 5' tgaaggagaaggtgtctgcggga
3' (forward) and 5' aggacggtgcggtgagagtg 3' (reverse). This resulted in a DNA
fragment of 198 bp. The PCR reaction was performed in a 50JlI reaction mix
containing 0.8 JlI (10 pmolll) of each primer, 4 JlI mix of the deoxynucleotide
triphosphates (dNTPs) (5 mM), 5 JlI of 10x PCR buffer and 1 JlI of Taq polymerase
(5U/JlI). Thermal cycling was started at 95°C for 1 minute, followed by 10 cycles
(95°C, 10 seconds; 60°C' 45 seconds; 72°C, 45 seconds) and a further 20 cycles
(95°C, 10 seconds; 57°C, 45 seconds; 72°C, 45 seconds) and a final extension step
for 1 minute at 72°C.
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2.6.3 MTHFR A1298C mutation
Genotyping was perfonned by PCR amplification and Mbo II digestion. The forward
primer is 5' atgtggggggaggagctgac 3' and the reverse 5' gtctcccaacttacccttctccc 3'.
The resulting DNA fragment is 241 bp in size. The PCR reaction was perfonned in a
50 ,...1reaction mix containing 1.5 ,...1(10 pmolll) of each primer,S ,...1mix of the dNTPs
(5mM), 5f.l1of 10x PCR buffer and 1,...1of Taq polymerase (5U/,...I).Thermal cycling
was started at 94°C for 1 minute 30 seconds, followed by 30 cycles (94°C, 30
seconds; 55°C, 45 seconds; 72°C, 1 minute) and a final extension step for 3 minutes
at 72°C.
2.6.4 LDLR promoter
To detennine the recently described -175GIT variant in the regulatory region of the
LDLR promoter, the primers used were 5' aggcagagaggacaatggc 3' (15pmol; 0.55
,...1,forward primer) and 5' cacgacctgctgtgtccaagcttgaaaccc 3' (15 pmol; 0.25 f.ll,
reverse primer) in a 50 ,...1reaction mix PCR buffer 10x, 5 ul, dNTPs (5mM) 10 f.ll and
Taq polymerase (5U1f.l1)0.15 ,...1were amplified with 1 ,...1of genomic DNA. Thennal
cycling was started at 95°C for 1 minute, followed by 10 cycles (95°C for 10 seconds,
60°C for 45 seconds, 72°C for 45 seconds) and another 30 cycles (95°C for 10
seconds, 58°C for 45 seconds, 72°C for 45 seconds).
2.6.5 LDLR: D154N, D200G, 652 del GGT and D206E mutations in exon 4
For this reaction, the primers 5' cccccagctgtgggcctgcg 3' (forward, 0.2 f.ll of a 20 pmol
solution) and 5' cgcccccaccctgccccgcc 3' (reverse, 0.2 ,...1of a 20 pmol solution) were
used. A reaction mix of 50,...1was used with 10 J.1I dNTPs (5mM), 5 ,...110xPCR buffer
mix, 0.1 ,...1Taq polymerase (5U/,...I)and 1 ,...1of genomic DNA as template.
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Thermal cycling was started at 95°C for 2 minutes and 30 seconds, followed by 35
cycles of 94°C for 1 minute, 71°C for 1 minute and 72°C for 2 minutes. The final
extension was done at 72°C for 10 seconds. A DNA fragment of 237 basepairs was
produced. Mbo II restriction digestion analysis was performed to detect the D154N
mutation.
2.6.6 LDLR: V408M mutation in exon 9
Primers H9 (5' cccctgacctcgctccccgg 3', forward primer, 0.33 JlIof a 20 pmol solution)
and J9 (5' gctgcaggcaggggcgacgc 3', 0.2 f.11of a 20 pmol solution, reverse primer)
was used in a 50 JlI total volume containing 10 JlIof the four dNTPs (10mM), 5 f.1110X
PCR buffer and 0.1 f.11Taq polymerase (5U/f.11).One microlitre of genomic DNA was
used as template.
The initial denaturation step of the PCR reaction was started at 95°C for 1 minute,
followed by 10 cycles (95°C for 5 seconds, 63°C for 30 seconds, 72°C for 30
seconds) and another 30 cycles (95°C for 5 seconds, 62°C for 30 seconds, 72°C for
30 seconds and a final extension step for 5 minutes at 72°C).
2.7 Restriction enzyme digestion
2.7.1 C677T Digest (Hinf I)
The C to T substitution at nucleotide position 677 creates a Hinf I recognition site for
enzymatic cleavage. The recognition sequence is 5' G. ANT C 3'
3' C TNA .G 5'
Hinf I (10U/JlI) supplied by Prorneqa Corporation was used. The restriction enzyme
buffer (10x) supplied with the enzyme (60mM Tris-HCl, 500mM NaCI, 60mM MgCI2,)
and acetylated bovine serum albumin (10 mg/ml) were used in the following
quantities: buffer 2.0f.11,bovine serum albumin 0.2JlI, distilled water 6.8JlI and Hinf I
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1.0f.l1and 10f.l1of amplified DNA product in a total volume of 201-1-1.Digestion was
performed in a water bath at 37°C for at least four hours. The 198 bp fragment (CIC,
undigested) is cut into 175 bp and 23 bp fragments if the mutation is present. Bovine
serum albumin was added as it enhances the activity of the restriction enzyme.
2.7.2 A1298C Digest (Mbo II)
The supplier of Mbo II (10UlI-I-I) was Amersham Pharmacia Biotech. The A to C
substitution abolishes a cleavage site for Mbo II in the wild type genome. The
fragment is cut into fragments of 204 and 37 basepairs. For the digest, the buffer
(10mM Tris-HCI, 7mM MgCI2, 10mM KCL, 7mM 2-mercaptoethanol, 0.01% BSA)
supplied with the restriction enzyme is used in the following quantities: 10x buffer 21-1-1,
distilled water 7.5f.l1, Mbo II 0.51-1-1and PCR product 101-1-1.Products were digested
overnight at 37°C.
2.8 Gel electrophoreses
Non-denaturing polyacrylamide gel solutions were used for restriction enzyme
analysis. A polyacrylamide gel was used, supplemented with 10% urea for the
V408M mutation analysis and supplemented with 10% glycerol for the combined
heteroduplex and single-strand conformation polymorphism (HEX-SSCP) analysis of
mutations D206E and D154N [Kotze et al, 1995]. The FV Leiden and prothrombin
mutations were resolved on 1% agarose gels. A urea HEX-SSCP gel was used for
the detection of the -175Gff LDLR promoter variant. For the restriction enzyme gels,
201-1-1of the digested product and 5 f.lIloading dye (appendix) were electrophoresed
for 2 hours at 250 volts at room temperature. Polyacrylamide gels were stained with
ethidium bromide before visualisation under ultra-violet light. Agarose gels were
prepared with ethidium bromide added to the gel to enhance visualisation of products
under ultra-violet light. A ficol! orange loading dye was used for agarose gels.
Stellenbosch University http://scholar.sun.ac.za
55
Chapter 3
Results and discussion
In this chapter, the most significant data are presented in tables, figures and graphs.
A representative photograph of each mutation is included. The data is then presented
in article format with articles already accepted or in preparation for publication.
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Table IV
Mutation detection: Results Group A (Control)
INumber IRace I Age I Homocystein IC677T IA1298C IFV Leiden IA2021 OG11Min Apgar I
A01 4 35 1 1 2 1 1 1
A02 4 24 1 1 1 1 1 1
A03 4 36 2 1 2 1 1 1
A04 4 26 1 2 2 1 1 1
A05 8 36 1 1 1 1 1 2
A06 4 28 1 1 2 1 1 1
A07 4 35 1 2 1 1 1 2
A08 4 28 1 1 1 1 1 1
A09 4 35 1 1 1 1 1 1
A11 4 36 2 1 1 1 1
A12 4 19 1 1 2 1 1 1
A13 4 28 2 1 2 1 1 1
A14 4 26 1 1 3 1 1 1
A15 4 28 1 1 2 1 1 1
A16 4 28 2 1 2 1 1 2
A17 8 22 1 1 2 1 1 1
. A18 4 23 2 1 1 1 1 1
A19 4 28 1 1 1 1 1 1
A20 4 29 2 1 1 1 1 1
A21 4 23 2 1 2 1 1 1
A22 4 37 1 2 1 1 1
A23 4 29 1 2 1 1 1 1
A24 4 25 2 2 2 1 1 1
A25 4 34 1 1 3 1 1 1
A26 4 35 1 1 1 1 1 1
A27 4 43 1 1 2 1 1 1
A28 4 36 2 1 1 1 1
A29 4 31 1 2 1 1 1 1
A30 4 34 1 1 1 1 1 1
A31 4 34 1 1 2 1 1
A32 4 29 1 1 1 1 1
A33 4 37 1 1 1 1 1
A34 8 19 1 1 1 1 1
A35 4 40 2 1 1 1
A36 4 27 1 2 2 1 1 1
A37 4 20 2 1 2 1 1 1
A38 4 18 1 1 2 1 1
A39 4 30 1 1 1
A40 8 26 1 1 1
A41 4 34 1 1 1
A42 4 39 1 1 1
A43 4 22 2 2 1 1 1
A44 4 28 1 1 2 1 1 1
A45 4 34 1 1 2 1 1 1
A46 4 33 2 3 1 1 1
A47 4 25 1 1 1 1 1 1
A48 8 29 1 1 1 1 1
A49 4 36 1 1 2 1 1 1
A50 4 22 1 1 1 1 1
Homocystein 1 = normal, 2 = >11 J.I. moUl
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1 minute Apgar: 1 = score above 5, 2 = score 5 or less
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table V
Mutation detection: Group B (Primigravidae <34 weeks)
1Number 1 Race I Age IHomocystein IC677 IA1298C 1FV Leiden 1A2021 OG 11 Min Apgar 1
851 2 31 1 2 1 1 1 1
852 4 16 1 1 2 1 1 0
853 8 26 1 1 3 1 1 0
854 4 37 2 1 1 1 1 0
855 4 20 1 1 1 1 1 0
856 8 26 1 1 1 1 1 0
857 4 17 1 1 2 1 2 2
858 4 21 1 1 1 1 1 1
859 8 19 1 1 1 1 2 1
860 8 16 2 2 1 1 1 2
861 8 19 1 1 1 1 1 1
862 8 24 1 1 1 1 1 1
863 4 24 1 1 1 1 1 1
864 8 20 1 1 3 1 1 0
865 8 24 1 1 2 1 1
866 4 21 1 1 1 1 1 2
867 8 21 2 1 1 1 1 2
868 2 26 2 1 1 1 1 1
869 4 26 1 1 3 1 1 1
870 4 16 2 1 3 1 1 1
871 8 15 2 1 3 1 1 2
872 4 22 1 1 2 1 1 1
873 4 21 2 2 1 1 1 0
874 8 22 1 1 1 1 1 1
875 4 19 2 1 3 1 1 2
876 8 29 1 1 1 1 1 1
877 4 27 2 1 1 1 1 1
878 4 21 1 1 3 1 1 2
879 8 17 2 1 1 1 1 2
880 4 19 1 1 1 1 1 0
881 8 16 2 1 3 1 1
882 4 24 1 2 1 1 1 2
883 4 16 1 2 1
884 4 25 1 1 1 1 1 1
885 4 20 2 2 1 1 1 2
886 4 17 2 1 1 1 1 1
887 8 26 2 1 1 1 1 0
888 8 23 2 1 2 1 1 1
889 4 20 1 2 1 1 1 0
890 4 14 1 1 2 1 1 1
891 4 21 2 2 1 1 1 2
892 8 22 2 1 2 1 0
893 8 20 2 2 2 1 1 1
894 8 25 1 1 1 2
895 4 18 2 1 1 1 1
896 4 20 1 1
897 4 18 2 1 1 1 1 1
898 4 23 2 1 2 1 1 0
899 4 28 1 1 2 1 1 1
8100 8 22 1 1 2
Homocystein 1 = normal, 2 = >11 Il mol/!
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1 minute Apgar: 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table VI
Mutation detection: Group C (Primigravidae> 34 weeks)
I Number 1Race 1 Age 1Homocystein 1CanT 1A1298C 1 FV Leiden 1A20210G 11 Min Apgar I
C101 8 20 1 1 2 1 1 2
C102 4 18 1 1 2 1 1 1
C103 4 17 2 1 2 1 1 1
C104 8 19 2 1 1 1 1 1
C105 8 20 1 1 2 1 1 0
C106 4 17 2 1 1 1 1 1
C107 4 29 1 1 2 1 1 1
C108 4 18 1 1 1 1 1 1
C110 4 28 1 2 2 1 1 1
C111 4 25 1 2 1 1 1 1
C112 8 20 1 1 1 1 1 1
C113 4 22 1 1 1 1 1 1
C114 4 19 2 1 2 1 1 1
C115 4 19 1 1 2 1 1 1
C116 4 18 1 1 1 1 1 2
C117 4 19 1 1 2 1 1 1
C118 4 21 1 1 2 1 1 1
C120 8 26 1 3 1 1 1
C121 8 20 1 1 1 1 1 2
C122 4 37 1 1 3 1 1 1
C123 4 19 1 1 1 1 1 2
C124 4 25 1 1 1 1 1 1
C125 4 25 1 2 2 1 1
C126 4 19 1 1 2 1 1 1
C127 4 25 1 1 1 1 1 1
C128 4 23 1 1 1 1 1 1
C129 8 16 2 1 1 1 1 1
C130 8 15 1 1 2 1 1 1
C131 4 21 1 2 1 1 1 1
C132 4 16 1 2 1 1 1 1
C133 4 19 1 1 1 1 1
C134 4 15 1 1 1 1 1 1
C135 4 25 1 1 1 1 1 1
C136 4 17 2 1 2 1 1 1
C137 4 19 2 1 2 1 1 1
C138 8 26 1 1 1 1 1 1
C139 4 20 1 1 2 1 1
C140 8 15 1 1 1 1 1 2
C141 4 25 1 1 1 1 1 1
C142 4 16 1 1 2 1 1 1
C143 4 24 1 2 1 1 1 1
C144 4 20 1 1 1 1 1 1
C145 4 19 1 1 1 1 1 1
C146 4 19 1 1 2 1 1 1
C147 4 22 1 1 2 1 1 1
C148 8 31 1 1 1 1 1 1
C149 4 19 1 2 1 1 1
C150 8 19 2 1
Homocystein 1 = nonnal, 2 = >11 IJ. molll
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1 minute Apgar: 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black.
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Table VII
Mutation detection: Group D (Multigravidae <34 weeks)
INumber I Race I Age 1Homocystein IC677 1A1298C 1FV Leiden IA20210G 11 Min Apgar I
0151 8 42 2 2 2 1 1 0
0152 8 31 2
0153 4 27 1 1 2 1 1 0
0154 4 25 1 2 1 1 1 1
0155 4 25 1 1 1 1 1 1
0156 4 34 2 2 1 1 1 1
0157 4 31 1 1 1 1 1 0
0158 4 40 1 1 1 1 1 1
0159 4 35 1 1 2 1 1 1
0160 4 31 1 1 2 1 1 0
0161 4 27 1 2 1 1 1 2
0162 4 33 1 1 1 1 1 1
0163 4 32 1 1 2 1 1 2
0164 8 29 2 1 1 1 1 0
0165 4 21 1 1 2 1 1 0
0166 4 32 2 1
0167 4 33 1 1 1
0168 8 31 1 1
0169 4 25 1 1 1 1 1 1
0170 8 33 2 1 1 1 1 2
0171 4 25 1 1 2 1 1 1
0172 8 26 1 2 1 1 0
0173 4 38 2 1 3 1 1
0174 4 25 1 1 1 1 1 0
0175 4 37 1 1 3 1 1 0
0176 4 23 1 2 2 1 1 1
0177 4 30 2 1 1 1 1 1
0178 8 27 1 1 1 1 1 1
0179 4 19 1 1 1 1 1 1
0180 4 25 2 1 2 1 1 0
0181 8 35 2 1 1 1 1 0
0182 4 25 1 1 1 1 2
0183 8 36 2 2 1 1 1 1
0184 8 29 2 2 1 1 1 1
0185 4 26 1 2 1 1 1 2
0186 4 27 1 1 2 1 1 2
0187 8 36 2 2 1 1 1 1
0188 8 31 1 1 1 1 1 1
0189 4 33 1 1 2 1 1 0
0190 8 27 2 2 1 1 1 2
0191 4 24 1 1 3 1 1 1
0192 4 41 1 1 1 1 1 1
0193 8 29 1 1 1 1 1
0194 4 25 1 1 3 1 1 0
0195 4 18 1 1 2 1 1 1
0196 8 26 1 1 1 1 1 0
0197 4 36 1 1 2 1 1 0
0198 4 30 1 1 1 1 1 0
0199 4 31 1 1 2 1 1 2
0200 4 28 1 1 1 1 1 1
Homocystein 1 = normal, 2 = >11 f.J. molll
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1 minute Apgar: 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table VIII
Mutation detection: Group E (Multigravidae >34 weeks)
INumber IRace IAge I Homocystein IC677 I A1298C IFV Leidenl A20210G 11 Min Apgar I
E201 4 29 1 1 3 1 1 1
E202 8 46 1 1 1 1 1 2
E203 4 18 1 1 3 1 1 1
E204 4 26 1 1 1 1 1
E205 4 37 1 1 2 1 1 1
E206 4 33 1 1 1 1 1 1
E207 4 33 1 2 1 1 1 1
E208 8 30 1 2 1 1 1 1
E209 4 36 1 1 3 2 1 1
E210 4 37 1 1 3 1 1 1
E211 4 30 1 1 3 1 1 2
E212 4 30 1 1 2 1 1 1
E213 4 20 1 1 2 1 1 1
E214 4 41 1 1
E215 4 21 1 2 1 1 1
E216 4 17 1 1 1 1 1
E217 4 26 1 1 2 2 1 1
E218 4 36 1 1 1 1 1 1
E219 4 26 1 1 1 1 1
E220 4 37 1 2 1 1 1 1
E221 8 29 1 1 3 1 1 1
E222 4 33 1 1 2 1 1 1
E223 8 39 1 1 2 1 1 1
E224 4 19 1 1 3 1 1 1
E225 4 34 1 1 2 1 1 1
E226 4 34 1 1 2 1 1 1
E227 4 40 1 1 1 1 1 1
E228 4 22 1 2 1 1 1 1
E229 4 20 1 1 1 1 1 1
E230 4 20 1 1 3 1 1 1
E231 4 32 1 1 1 1 1 1
E232 8 25 1 1 1 1 1 1
E233 4 32 1 1 3 1 1 2
E234 4 25 1 2 1 1 1 1
E235 8 23 1 1 1 1 1 1
E236 4 27 1 1 1 1 2
E237 8 37 1 1 2 1 1 1
E238 4 25 1 1 1 1 1
E239 4 22 1 1 3 1 2
E240 4 26 1 2 2 1 1
E241 8 31 1 1 1 1 1
E242 4 19 1 1
E243 8 26 1 1
E244 4 28 1 1 1 1 1
E245 8 25 1 1 1 1 1
E246 4 26 1 1
E247 4 20 1 1 2 1 1
E248 4 29 1 1 1 1
E249 4 35 1 1 1 1
E250 4 29 1 1 1 1
Homocystein 1 = normal, 2 = >11 Il molll
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1 minute Apgar: 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table IX
Mutation detection: Group F (Primigravidae PIH)
INumber IRace IAge IHomocystein IC677 IA1298 IFV Leiden 1A20210G11 Min Apgar I
F251 4 22 1 1 2
F252 4 23 1 2 2
F253 4 19 2 1 2
F254 4 17 1 1 1
F255 4 32 1 1 3
F257 4 23 1 1 1
F258 4 16 1 1 3
F259 8 24 1 1 3
F260 4 15 1 1 3
F261 4 20 1 1 1
F262 8 24 1 1 2
F263 4 32 1 1 2
F264 8 29 1 1 1
F265 4 15 1 1 1
F266 4 21 1 1 2
F267 4 15 1 1 1
F268 4 17 1 1 1
F269 4 26 1 1 1
F270 4 18 1 1 3
F271 4 19 1 1 1
F272 4 21 1 1 2
F273 4 30 1 1 2
F274 4 22 2 2 2
F275 4 23 1 1 1
F276 4 20 1 1 2
F277 4 19 1 1 1
F278 8 19 1 1 1
F279 4 15 1 1 2
F280 4 28 1 1 2
F281 4 15 1 1 2
F282 4 15 1 1 2
F283 4 26 1 1 3
F284 4 14 1 1 1
F285 8 25 1 1 1
F286 4 24 1 2 2
F287 4 23 1 1 2
F288 4 37 1 1 2
F289 4 20 1 1 1
F290 4 17 1 1 2
F291 4 23 1 1 3
F292 8 28 1 1 2
F293 4 28 1 1 2
F294 8 24 1 1 1
F295 4 19 1 1 1
F296 4 30 1 1
F297 4 24 1
F298 4 24 2
F299 4 27 2
F300 4 20 1
Homocystein 1 = normal, 2 = >11 ~ molll
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 2
1 1 1
1 1 1
1 1 1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1 minute Apgar: 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table X
Mutation detection: Group G (Multigravidae PIH)
INumber IRace I Age I C677T I A1298C I FV Leiden I A20210G 11 Min Apgar I
G301 8 24 1 1 1 1 1
G302 4 25 1 2 1 1 1
G303 4 37 1 2 1 1 1
G304 8 34 1 2 1 1 1
G305 8 36 1 1 1 1 1
G306 4 35 1 1 1 1 1
G307 8 23 1 2 1 1 2
G308 4 42 1 2 1 1 1
G309 4 43 1 2 1 1 1
G310 4 35 1 1 1 1 1
G311 4 37 1 1 1 1 1
G312 8 26 1 1 1 1
G313 4 26 1 2 1 1 2
G314 4 36 1 3 1 1 1
G315 8 30 1 2 1 1 1
G316 4 28 1 1 1 1 1
G317 4 40 2 1 1 1 1
G318 4 29 1 2 1 1 1
G319 8 26 1 3 1 1 1
G320 8 32 1 1 1 2
G321 4 35 2 1 1 1
G322 4 33 1 1
G323 4 29 1 1 1 1 1
G324 4 33 1 3 1 1 1
G325 4 38 1 2 1 1 1
G326 4 32 2 2 1 1 1
G327 4 33 1 2 1 1 1
G328 8 34 1 2 1 1 1
G329 4 30 1 3 1 1 2
G330 8 29 1 2 1 1 1
G331 8 35 1 3 1 1 1
G332 8 30 1 1 1 1 1
G333 4 31 1 2 1 1 1
G334 4 34 1 1 1 1 1
G335 8 26 1 1 1 1 1
G336 4 28 1 1 1 1
G337 4 25 1 1 1
G338 8 32 1 1 1 1
G339 4 29 1 2 1 1
G~O 4 ~ 0
G~1 4 W 1
G342 4 37 2 1 1 1 1
G343 8 25 1 2 1 1 0
G344 4 39 2 2 1 1 1
G345 4 35 1 3 1 1 1
G346 4 27 1 2 1 1 1
G347 4 25 1 2 1 1 1
G348 4 36 1 2 1 1 1
G349 4 37 1 1 1 1 1
G350 4 38 1 2 1 1 1
Mutations: 1 = wild-type (-1-),2 = heterozygous state (+/-),3 = homozygous mutant (+/+)
1 minute Apgar: 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table XI
Mutation detection: Group H (Abruptio placentae)
'Numberl Race' Age' C677T' A1298C' FV Leiden' A20210G 11 Min Apgar'
H351 4 36 1 1 1 1 0
H352 4 34 1 1 1 1 1
H353 4 33 1 2 1 1 0
H354 4 27 1 2 1 1 0
H355 8 36 1 1 1 1 0
H356 8 40 1 3 1 1 0
H357 4 38 1 1 1 1 1
H358 4 24 1 1 1 1 1
H359 4 31 1 1 1 1 0
H360 8 25 1 1 1 1 0
H361 4 36 1 2 1 1 2
H362 8 35 2 1 1 1 0
H363 4 35 1 1 1 1 1
H364 8 29 2 1 1 0
H365 4 25 1 1 1 2
H366 4 26 1 1 1 0
H367 4 19 3 1 0
H368 4 35 2 1 1 1
H369 4 18 2 1 1 0
H370 8 22 1 2 1 0
H371 4 28 2 2 1 0
H372 8 28 1 1 1 0
H373 4 19 1 1 1 1
H374 4 28 1 2 1 0
H375 8 22 1 1 1 1
H376 4 29 1 1 1 0
H377 4 32 1 1 1 0
H378 4 42 1 3 1 0
H379 4 35 1 1 2
H380 4 38 1 2 1 2
H381 4 19 1 1 1 1 2
H382 4 32 2 2 1 1 0
H383 4 23 2 2 1 1 1
H384 4 27 1 1 1 1 0
H385 4 31 1 2 1 1 0
H386 8 32 1 1 1 1 0
H387 4 30 1 2 2 1
H388 4 28 1 1 1 1 0
H389 2 18 1 2 1 1 0
H390 8 21 1 1 1 1 0
H391 4 22 2 1 1 1 0
H392 4 19 1 1 1 1 0
H393 4 20 1 1 1 1 1
H394 4 20 1 1 1 1 1
H395 4 16 1 1 1 1 0
H396 4 17 1 2 1 1 0
H397 4 20 1 2 2 1 0
H398 4 37 1 3 1 1 0
H399 4 21 2 1 2
H400 4 33 1 3 1 1 0
Mutations: 1 = wild-type (-/-), 2 = heterozygous state (+/-), 3 = homozygous mutant (+/+)
1 minute Apgar. 1 = score above 5, 2 = score 5 or less, 0 = fetal death
Race: 2 = Caucasian, 4 = Coloured, 8 = Black
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Table XII
Mutation detection: Results Group L
Nr I RIG I P I A IBMII s-e I 677112981 LDLR I FH1 I FH31 FH2 I X2 I PL I SFG IPH I MO I
L1 4 6 5 1 46 1 2 1 1 1 1 1 2 1 1 3
L2 4 4 2 1 33 1 1 1 1 1 1 1 1 1 6 1
L4 4 1 0 2 23 3 1 2 1 1 1 1 1 1 2
L5 a 1 0 1 24 1 1 3 1 1 1 1 4
L6 a 3 2 0 23 1 2 1 1 1 2 1 1 4
L7 4 7 5 1 29 1 1 1 2 1 1 1 2 2
La 4 2 1 1 40 1 3 1 1 1 1 1 1 2
L9 4 2 1 1 23 1 1 1 1 1 2 1 5 1
L10 4 2 1 1 34 1 1 3 1 1 1 1 1 1
L13 4 3 2 1 29 1 1 1 1 1 1 1 1 1
L15 4 3 0 1 30 1 1 1 1 1 1 1 6 1
L17 4 5 3 1 33 2 1 2 1 1 1 1 1 2
L18 4 5 1 24 1 1 2 1 1 2 1 2 1
L19 4 4 3 1 37 1 1 1 2 1 1 1 1
L20 a 4 3 1 34 3 1 2 1 1 1 1 1 1
L21 4 6 3 1 1 1 2 1 1 1 1 6 1
L22 4 2 1 1 41 2 1 1 1 1 1 1 1 2
L23 4 3 1 1 20 3 1 2 1 1 1 1 1 1
L24 4 3 2 1 32 1 1 2 1 1 1 3 2
L26 4 3 2 1 17 1 2 1 1 1 2 1 6 1
L29 4 4 3 0 0 1 2 1 1 1 3 3 1 1
L30 4 6 5 1 36 1 2 1 1 1 1 1 1 1
L33 4 7 1 0 27 1 1 1 1 3 3 6 1
L34 4 2 1 1 28 3 1 1 1 1 1 1 1
L35 4 1 0 1 23 3 2 1 1 1 1 1 1
L36 4 1 0 1 22 1 1 2 2 1 1 1 1
L12 4 2 0 1 29 1 1 1 1 1 1 6 1
L16 a 10 7 1 34 1 1 1 1 1 1 1 1 1 1
L28 4 2 1 1 1a 2 1 2 1 1 1 1 1
L31 4 3 2 1 21 1 2 1 1 1 2 1
L39 4 6 1 36 1 2 1 1 1 1 1 1 3 4
L40 4 4 3 1 31 1 2 1 2 1 1 1 1 1 1
L41 4 1 0 1 19 1 2 1 1 1 1 1 1 1 1
L42 4 5 1 28 1 1 1 1 1 1 2 1 1 1
L44 4 4 3 1 23 1 2 1 1 1 1 1 3 1
L45 8 4 3 1 19 1 2 1 1 1 1 2 2 2 1
L46 4 2 1 1 51 1 1 2 1 1 1 1 1 3 2
L47 4 4 0 0 18 1 1 3 1 1 1 3 3 6 1
L48 4 4 3 1 25 2 1 1 1 1 1 1 2 1
L49 8 3 1 1 29 1 1 1 1 1 1 1 2 1
L50 4 5 1 30 1 1 1 1 1 1 1 1 2 1
L51 4 4 0 0 35 1 1 1 1 1 1 3 3 6 1
L53 4 1 0 1 21 1 2 2 2 1 1 1 1 1 1
L54 4 6 4 1 48 1 1 1 1 1 1 1 2 2
L56 4 4 1 0 27 1 1 2 1 1 1 3 3 1 1
L5a 4 2 1 1 2 1 1 1 1 1 1 1 1 1
L59 4 2 1 1 28 1 1 2 1 1 1 1 1
L60 4 2 1 1 24 1 2 1 1 1 1 2 1 1 1
L61 4 3 1 0 27 1 2 1 1 1 1 3 3 2 1
L62 4 2 0 1 32 1 1 2 1 1 1 1 1 1 1
L63 4 3 2 1 25 1 1 2 1 1 1 1 2 1
L64 4 3 2 1 20 1 2 1 1 1 1 1 1 1 1
L105 8 2 0 1 23 2 1 1 1 1 1
L65 4 2 1 1 0 3 2 2 1 1 1 2 1 1 1
L66 4 3 2 0 25 1 2 1 1 1 1 2 1 1
L67 4 2 1 1 33 1 1 1 1 1 2 1 1 3
L70 4 1 0 1 29 1 1 1 1 1 1 1 1 1
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Nr 1 RI 1 PiA 1BMq S-c 1677112981 LDLR 1FH1 1FH31 FH21 X2 1PL 1SFG 1PH 1MO 1G
L71 4 6 3 1 34 2 1 1 1 1 1 1 2 1 1 1
L73 4 5 3 1 34 1 2 1 1 1 1 1 1 2 1
L74 4 3 0 0 21 1 2 2 1 1 3 3 6 1
L75 4 3 2 1 21 1 2 1 1 1 1 1 2 1
L76 4 1 0 1 0 1 2 1 1 1 1 1 2
L77 4 1 0 1 0 1 1 2 1 2 2 1 3
L124 8 3 2 1 43 1 1 2 1 1 1 1 1 1 4
L80 4 1 0 1 25 2 1 2 1 1 1 1 1 1 1
L81 4 4 3 1 36 2 2 1 1 1 1 1 1 1 2
L82 4 1 0 1 26 1 1 2 1 1 1 2 2 1 1
L83 4 3 2 1 22 1 1 1 1 1 1 1 1 1 2
L84 4 5 2 1 26 1 1 2 1 1 2 2 6 1
L85 4 3 2 1 0 1 1 1 1 1 2 1 2 1
L88 4 5 3 2 38 1 1 2 1 1 2 2 1 2
L89 4 3 1 1 23 3 2 1 1 1 1 1 1
L90 4 3 0 1 23 1 1 1 1 1 1 1 1 3 1
L91 4 3 2 2 33 1 1 1 1 1 1 1 3 2
L92 4 1 0 1 23 1 1 3 1 1 1 2 2 1 1
L93 4 4 1 0 26 1 2 2 1 1 1 3 3 1 1
L94 4 1 0 1 26 1 1 1 1 1 1 1 1 1 1
L95 4 3 2 1 35 1 1 2 1 1 1 1 1 1 2
L96 8 3 2 1 22 1 1 1 1 1 1 1 2 1 1
L97 4 5 3 1 30 1 2 1 1 1 1 1 1 4
L98 4 2 1 1 33 1 1 1 1 1 1 1 1 3 1
L99 8 1 0 1 24 3 1 1 1 1 1 1 1 1 1
L100 4 3 2 1 20 1 1 1 1 1 1 1 2 1
L101 4 3 0 32 1 1 1 2 1 1 6 1
L103 4 2 1 21 1 1 3 1 1 1 1 1 2 1
L104 4 1 0 25 1 1 2 1 1 1 1 1 1 1
L106 2 1 0 27 2 1 2 1 1 1 1 1 1 2
L107 4 1 0 20 1 1 2 1 1 1 1 1 3
L108 4 4 3 27 1 1 1 1 1 1 1 1 1
L109 8 1 0 39 1 1 1 1 1 1 1 1 2
L110 4 1 0 29 2 1 1 1 1 1 1 2 1 2
L111 4 2 32 1 1 2 1 1 2 1 6 1
L112 4 2 0 39 1 1 2 2 1 1 1 6 1
L113 4 3 2 21 1 1 1 1 1 1 1 2 2
L114 4 2 1 20 1 1 1 1 1 1 3 3 1 1
L115 4 3 2 2 28 1 2 1 1 1 1 1 1 1 1
L116 8 5 1 1 1 1 1 1 1 1 1 6 1
L117 4 3 2 1 38 1 2 1 1 1 1 1 1
L118 4 4 3 0 32 1 1 2 1 1 1 3 3 2 1
L119 4 2 1 1 0 2 2 2 1 1 1 2 1 1
L120 8 7 5 1 39 1 2 2 1 1 1 1 2 1
L122 8 5 4 1 31 2 1 1 1 1 1 1 1 1 1
L123 8 5 0 0 33 1 1 1 1 1 1 1 3 3 6 1
L125 4 1 0 1 25 1 3 1 1 1 1 1 1 1
L126 2 1 0 1 22 3 1 1 1 1 1 1 1 1 1
L128 4 6 4 1 0 1 2 2 1 1 1 1 1 1 1
L129 4 2 1 2 31 1 1 2 1 1 1 1 1 1
L131 4 5 1 26 1 1 2 1 1 1 1 1 1
L132 4 5 4 1 33 1 1 2 1 1 1 1 1 1 1
L133 4 5 4 0 32 1 2 1 2 1 1 1 1 2 1
L134 4 2 1 1 25 1 1 1 1 1 1 1 1 1 2
L135 4 4 3 1 22 1 1 2 1 1 1 1 1 2 1
L136 4 3 3 1 36 1 1 1 1 1 1 1 1 1 1
L137 4 7 2 0 1 1 2 1 1 3 3 1 1
L3 4 2 1 35 1 1 1 1 1 1 1 1
L11 4 2 1 3 1 1 1 1 1
L14 2 2 1 1 1 1 1 1 1 1 1
L32 4 3 22 1 1 1 1 1 3 1
L37 4 1 1 2 1 1 1
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1 Nr 1RIG 1 PiA IBMII S-c 1677112981 LDLR 1FH1 1FH31 FH2 1 X2 1PL 1SFG IPH IMO 1
L43 4 2 1 2 1 1 1
L57 4 3 1 2 1 1 4
L72 8 2 1 1 1 1 1
L86 4 3 2 25 2 1 2 1 1
L87 8 5 1 1 1 2 1 1 1
L127 4 4 3 1 1 2 1 1
L130 4 4 1 3 1 1 1
Key to legend: Group L
Nr Number
R Race: 2 = Caucasian, 4 = Coloured, 8 = Black
G Gravidity
P Parity
A Apgar score: score >5 = 1; 5 or less = 2, fetal death = 0
BMI Body mass index (height in kg/length in m squared)
S-C Serum cholesterol: 1 = normal, 2 = probable familial
hypercholesterolaemia, 3 = possible familial hypercholesterolaemia
677 MTHFR C677T mutation: 1 = wild-type (-/-); 2 = heterozygote (+/-); 3 =
homozygote (+/+)
1298 MTHFR A1298C mutation: 1 = wild-type (-/-); 2 = heterozygote (+/-); 3 =
homozygote (+/+)
LDLR LDLR promoter mutation -175GIT: 1 = mutation absent, 2 = mutation
present
FH1 D206E LDLR mutation: 1 = absent
FH2 V408M LDLR mutation: 1 = absent
FH3 D154N LDLR mutation: 1 = absent
X2 6bp deletion in Exon 2 of LDLR mutation: 1 = absent
PL Preterm labour: 1 = none, 2 = preterm labour, 3 = miscarriage
SFG Fetus small for gestational age 1 = normal, 2 = SFG, 3 = miscarriage
PH Previous history: 1 = none, 2 = previous intra-uterine death, 3 = previous
hypertension,4 = previous pre-eclampsia, 5 = previous preterm labour,
6 = previous miscarriage
MO Maternal outcome: 1 = normal, 2 = hypertension, 3 = develops pre-eclampsia,
4 = preterm labour
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Figure V
Allele frequencies of the C and T alleles of the C677T MTHFR mutation: racial
distribution
100
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0
Coloured Black
p=0.0246, OR 2.08 (95%CI 1.05-4.21)
The mutated T allele of the C677T mutation occurs significantly more frequently in
the Coloured (mixed ancestry) population than in the Black population.
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Figure VI
Allele frequency of the A and C alleles of the A1298C MTHFRmutation: racial
distribution
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0/0 DA allele40
• C allele30
20
10
0
Coloured Black
p = 0.0407, OR 1.80 (95% Cl 1.14-2.83)The mutated C allele occurs significantly
more frequently in the Coloured population than in the Black population.
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Figure VII
Genotype frequency of the C677T MTHFR mutation: association with
hyperhomocysteinaemia
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p = 0.0095 OR 2.27 (950/0Cl 1.15-4.46)
The mutated T allele is significantly associated with hyperhomocysteinaemia
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Figure VIII
The incidence of elevated homocystein levels: racial distribution
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.p = 0.0033
0>11 (elevated)
.<11
There were significantly more Black patients with abnormal homocystein levels (all
patient groups combined).
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Figure IX
The relationship between elevated homocystein levels and neonatal outcome
(1 minute Apgar score)
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Total 150
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cohort 100
50
0
<5 >5 IUD Live
birth
There is a significant association between elevated homocystein level and
• a one minute Apgar Score of 5 or less (p = 0.043)
• intra-uterine death (p = 0.046)
Homocystein
levels
El >11(elevated)
D <11
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Figure X
Abnormal homocystein levels: distribution between patient groups
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A significant number (43%) of primigravidas with early onset, severe pre-eclampsia
had hyperhomocysteinaemia when compared with the other groups (p = 0.0396).
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Figure XI
C677T mutation detection
A B C o
'"
A representative photograph of a wild type individual (CIC), lane Band C. A single,
undigested 198 bp band is observed.
In lane A, homozygosity (TIT) for the mutation is demonstrated by a 175 bp fragment. In lane D,
heterozygosity is shown by the presence of both bands (mutant allele digested, wild-type allele
undigested).
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Figure XII
MTHFR Mutation A1298C
A 8 C o
................................................................._ ,,~~--~ _~ ~~~ ···....241bp
bp
Representative photograph of mutation A1298 analysis. The mutation abolishes a Mbo II
cleaving site present on the wild-type allele.
Lane A: Digested 204 bp fragment in a normal (wild-type) individual
Lane B: Two fragments at 241 bp and 204 bp indicating heterozygosity for the mutation.
Lane 0: Undigested 241 bp fragment in a homozygous mutant individual.
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Figure XIII
Factor V Leiden mutation
A1 A2 81 82 C1 C2 01 02
... 174 bp
Allele specific peR analysis for the factor V Leiden mutation:
Lane A: Wild-type individual (A1 normal primer, A2 mutant annealing primer; no annealing)
Lane C: DNA from heterozygous individual annealing with both the wild-type primer (C1) and the mutant primer
(C2).
Stellenbosch University http://scholar.sun.ac.za
77
Figure XIV
Simultaneous prothrombin A20210G and factorV Leiden mutation detection
A1 A2 81 82 C1 C2
.. 340 bp
.. 174 bp
Multiplex allele specific PCR for factor Vand Prothrombin A2021OGmutation.
Lane C1 and C2: annealing of the wild-type and mutant primers, respectively. At 340 bp, two fragments
representing heterozygosity at this locus (prothrombin).
174 bp: fragment in wild-type lane only, representing wild-type homozygosity for factor V Leiden
mutation.
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Figure XV
LDLR exon 48 (mutations D206E and D154N)
A 8 eDE F
A D206E mutation
B D154N mutation
C-F Individuals negative for both mutations
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3.1 Combined heterozygosity for methylenetetrahydrofolate reductase (MTHFR)
mutations C677T and A1298C is associated with abruptio placentae but not
with intrauterine growth restriction.
Gabriël S Gebhardt, Charlotte L Scholtz*, Renate Hillermann, Hein JOdendaal
Department of Obstetrics and Gynaecology, *Division of Human Genetics, Faculty of
Medicine, Tygerberg Hospital, Stellenbosch University and MRC Research Unit for
Perinatal Mortality, South Africa.
(Paper accepted for publication, European Journal of Obstetrics and Gynecology and
Reproductive Biology).
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Abstract
Objective. This study was undertaken to investigate the involvement of MTHFR gene
mutations C677T and A1298C implicated in vascular disease, in patients with
abruptio placentae and intrauterine growth restriction (IUGR).
Study design: DNA was extracted from blood samples of 54 patients with placental
vasculopathy (18 patients with abruptio placentae and 36 with IUGR) and 114 control
patients and amplified by the polymerase chain reaction. The resulting fragments
were subjected to restriction enzyme analysis and resolved by gel electrophoresis.
Results: A significant association could be demonstrated between mutation A 1298C
and both abruptio placentae and IUGR. Combined heterozygosity for mutations
C677T and A 1298C was detected in 22.2% of abruptio placentae cases.
Conclusions: Combined heterozygosity for MTHFR mutations C677T and A1298C
may represent a genetic marker for abruptio placentae.
Keywords: MTHFR combined heterozygosity, abruptio placentae
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1. Introduction
Abruptio placentae is the most common cause of intrauterine death at our institution
and the second most frequent cause of perinatal death after preterm labour (1). It is
the primary cause of fetal distress in patients where early onset severe pre-
eclampsia is treated expectantly (2). Within this population, at least 36% of patients
with severe pre-eclampsia also present with IUGR (3).
Abruptio placentae was associated with biochemical hyperhomocysteinaemia in the
population served by our institution (4). Elevated homocystein levels have been
shown to damage the vascular endothelium (5) and result in placental vasculopathy
(6). There are several documented mutations in the gene encoding
methylenetetrahydrofolate reductase (MTHFR) which is involved in the remethylation
of homocystein to methionine. Homozygosity for a mutated MTHFR gene was found
to be a risk factor for placental vasculopathy (7) while the A 1298C mutation has been
associated with decreased MTHFR activity and neural tube defects (8).
This study was designed to determine the prevalence of the MTHFR enzyme defects
in the local population and to investigate their role in abruptio placentae and IUGR.
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2. Subjects and methods
2.1. Clinical
The first study group (n=18) comprised patients who delivered at our institution in the
period 1 January to 31 December 1996 with the pregnancy complicated by abruptio
placentae. Only patients from the immediate catchment area were approached and
requested to participate. Abruptio placentae were diagnosed clinically and
subsequently confirmed when more than 15% of the placental surface was covered
with blood clots. After informed consent was obtained, five millilitres of blood was
collected in an EDTA-tube and sent to the laboratory for subsequent analysis.
The second study group (n=36) comprised mothers with IUGR identified at the fetal
evaluation clinic where all cases with possible poor fetal growth (symphysis-fundus
measurements below the tenth centile for gestational age) are evaluated (9).
Doppler flow velocity waveforms of the umbilical artery, determined by a continuous
wave Sonicaid Vasoflow machine with a 100Mhz filter, were used to differentiate
between IUGR and a constitutionally small fetus. Intrauterine growth restriction is
defined as a resistance index (RI) above the 95th centile (10). The study was
explained to these patients and informed consent obtained. Blood was collected in
EDTA tubes and sent to the laboratory for further analysis.
The control group was recruited from pregnant patients attending their first antenatal
clinic. In the period 15 July 1999 - 15 September 1999, 114 consecutive new
patients were invited to participate in the study. Venous blood was collected in EDTA
tubes for DNA extraction following informed consent.
All patients at this institution receive prophylactic iron and folate supplements during
the antenatal period. The majority (91%) of individuals included in this study is from
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the mixed ancestry (Coloured) indigenous population of South Africa (study group
50/54 [93%]; control group 103/114 [90%]). The Coloured population of South Africa
originated in the seventeenth century after union between European males and
females of two indigenous populations, the Khoi and the San (11).
2.2. Mutation detection
Genomic DNA was extracted from whole blood (12) and amplified by the polymerase
chain reaction (PCR) using previously described oligonucleotides (13). Amplified
products (198 and 163 basepairs) were digested with Hint I and Mbo II restriction
enzymes for detection of the C677T and A1298C mutations at the MTHFR locus,
respectively. Restricted products were resolved on 12% and 20% polyacrylamide
gels respectively, and visualised under UV light following ethidium bromide staining.
The frequency of the MTHFR mutations in the two study groups was compared with
that of the control group. Chi-square, Fisher's exact tests (where appropriate) and
odds ratios were used to compare categorical data. Statistical analysis was
performed by an independent statistician using Epi-info version 6.04, the statistical
package from the Centers for Disease Control.
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3. Results
The frequency of the mutant 677T allele did not differ significantly between the
mothers with abruptio placentae (13.9%) or IUGR (11.1%) and the control group
(14.9%) [Table I]. No homozygotes for the C677T mutation was detected in either of
the study groups but could be identified in two (1.75%) of the mothers in the control
group. In contrast, the A1298C mutation occurred significantly more frequently in
mothers who developed abruptio placentae (p=O.0157) and in mothers who had
IUGR (p=O.0192)when the frequency of the C allele is compared with that of the
control group [Table II].
Combined heterozygosity for mutations C677T and A1298C was identified in 4
(22.2%) of mothers who developed abruptio placentae, 2 (5.6%) of mothers who had
IUGR and in 4 (3.5%) of the control group. The abruptio group differed significantly
from the control group [Table III].
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4. Discussion
In this study, MTHFR mutation C677T did not occur more frequently in patients who
had abruptio placentae or IUGR than the control group. This compares favourably
with the recent study by Chikosi et al,. who could not identify more C677T mutations
in a cohort of Zulu mothers who developed pre-eclampsia (14). This would suggest
that the 677T mutant allele, per se, does not represent a major susceptibility
locuslfactor for abruptio placentae or IUGR in these South African ethnic groups, in
whom gestational vascular disease is common.
Homozygosity for the mutant T allele of mutation C677T (combined with wildtype AA
genotype of mutation A1298C) was identified exclusively in two individuals from the
control group. This status is usually associated with reduced MTHFR activity,
elevated plasma homocystein and reduced folate levels and these individuals would
usually be distinguishable biochemically. In contrast, homozygosity (and
heterozygosity to a lesser extent) for mutant allele 1298C is characterised by
reduced MTHFR activity but plasma homocystein and folate levels within the normal
range (15). Consequently individuals with this genotype would normally escape
detection by conventional plasma screening, reinforcing the value of DNA testing.
Plasma homocystein levels and serum and plasma folate and vitamin 812 status
were not determined in this study.
Strikingly, when combinations of the mutations were examined in this study,
combined heterozygosity for the two mutations was found to occur in almost a
quarter of the abruptio cases [odds ratio 5.14 (95% Cl 1.05-24.47)]. Could this
represent a susceptibility/predisposition factor for abruptio placentae? The apparent
combined effect of the two mutations would suggest that variant A1298C represents
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an abruptio placentae susceptibility factor which can be triggeredlinfluenced by a
modifier factor, in this case, variant C677T.
In this study, the A1298C mutation occurred significantly more commonly in the
abruptio and IUGR group than in the control cohort implicating this allele as a minor
susceptibility marker for placental vasculopathy. Interestingly, a role for this
sequence variant as a possible contributing factor to neural tube defects (NTDs) has
previously been proposed (8). Further studies are warranted to elucidate any
molecular links between placental vasculopathy and NTDs, both of which may result
from low levels of folate and/or raised homocystein levels.
A previous study from our institution demonstrated significantly higher serum
homocystein levels in patients who had abruptio placentae when compared with a
control group (4). Red blood cell count, serum folate, vitamin 86 and 8121evels did not
differ significantly although folate levels were lower in the abruption group. In a case
control study at the same institution, no significant differences could be demonstrated
in the nutritional status of mothers who had had abruptio placentae when compared
with a control group from the same residential area (16). It is therefore likely that
genetic factors playa more important role than nutritional conditions in our
population. Folic acid appears to be the most important supplement; as little as 0.65
mg per day (3.25x the recommended daily allowance) has been shown to normalise
homocystein levels (17). Chronic alcohol misuse is associated with raised
homocystein levels and administration of folic acid, vitamin 86 and 812 corrected this
(18). Quitting cigarette smoking is another way of reducing elevated homocystein
levels (19).
Raised homocystein levels can be normalised by supplementation with folic acid,
vitamin 86 (17) and vitamin C (20). Folic acid and vitamin 8 supplementation in
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particular is effective in lowering homocystein levels in patients with TT and CT
genotypes for the 677CT MTHFR mutation (21). Future studies will focus on whether
i) a correlation exists between MTHFR mutation status and the clinical presentation
of placental vasculopathy and ii) intervention with folic acid and vitamin B
supplementation in mutation positive mothers is likely to be beneficial in reducing the
incidence and recurrence of abruptio placentae.
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Table I
Genotype distribution of MTHFR mutations C677T and A1298C in abruptio
placentae, intrauterine growth restriction and a control group. Percentages are
shown in brackets.
Abruptio placentae IUGR Control
n = 18 n =36 n = 114
Mutation C677T a b c
Genotype
CC 13 (72%) 28 (78%) 82 (72%)
CT 5 (28%) 8 (22%) 30 (26%)
TT 0 0 2 (2%)
Mutation A1298C d e f
Genotype
AA 6 (33%) 16 (44%) 70 (61%)
AC 9 (50%) 14 (39%) 39 (34%)
CC 3 (17%) 6 (17%) 5 (4%)
a vs. c: odds ratio 0.99; 95% Cl 0.28 - 3.30; P= 0.7974
b vs. c: odds ratio 0.73; 95% Cl 0.27 - 1.91; P = 0.6343
d vs. f: odds ratio 3.18; 95% C11.01 -10.37; P = 0.0473
e vs. f: odds ratio 1.99; 95% Cl 0.07 - 4.55; P= 0.1095
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Table II
Allele frequencies of MTHFRmutations C677T and A1298C in abruptio
placentae, intrauterine growth restriction and a control group. Percentages are
shown in brackets:
Abruptio placentae IUGR Control
n = 18 n=36
n = 114
Mutation C677T a b c
C 31 (86%) 64 (89%) 194 (85%)
T 5 (14%) 8 (11%) 34 (15%)
Mutation A1298C d e f
A 21 (58%) 46 (64%) 179 (79%)
C 15 (42%) 26 (34%) 49 (21%)
a vs. c: odds ratio 0.92; 95% Cl 0.29-2.72; P = 0.926
b vs. c: odds ratio 0.71; 95% Cl 0.29-1.71; P = 0.538
d vs. f: odds ratio 2.61; 95% CI1.18-5.77; P = 0.015*
e vs. f: odds ratio 2.06; 95% Cl 1.12-3.82; P = 0.019*
*Statistically significant at p<0.05
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Table III
Combined genotype distribution of MTHFRmutations C677T and A1298C in
patients with abruptio placentae, intrauterine growth restriction and a control
group.
Mutation Mutation Abruptio IUGR (>95%)t Controls
C677T A1298C placentae (n=36) (n=114)
(n=18)
CC AA 5 10 42
CC AC 5 12 35
CC CC 3 6 5
CT AA 1 6 26
CT AC 4 2 4
CT CC 0 0 0
TT AA 0 0 2
TT AC 0 0 0
TT CC 0 0 0
Combined a b c
heterozygosity 4 (22%) 2 (5.6%) 4 (3.5%)
a vs. c:
bvs. c:
odds ratio 5.14; 95% C11.05 -24.47; P = 0.0306*
odds ratio 1.06; 95% Cl 0.14-6.22; P= 0.6135
t 95th centile refers to Doppler flow velocity waveforms in the umbilical artery
* Statistically significant at p<0.05
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Abstract
Objective
To investigate the hypothesis that pre-eclampsia is associated with atherogenic lipid
profiles and corresponding disease-causing mutations in the low-density lipoprotein
receptor (LDLR) gene.
Design
One hundred and twenty six consecutive patients were recruited at their first
antenatal visit. Blood was obtained for DNA extraction and fasting serum lipograms.
The eventual pregnancy outcome was correlated with seven LDLR mutations that are
relatively common in South African patients with familial hypercholesterolaemia.
Methods
Maternal DNA was genotyped for mutations V408M, D206E, D200G, D154N, 561 del
GGT, -175GfT promoter polymorphism and a 6 bp deletion in exon 2 of the LDLR
gene using polymerase chain reaction amplification, gel electrophoresis and
restriction enzyme analysis.
Results
None of the mutations screened for in the coding region of the LDLR gene were
detected in the study population, including 10 patients with abnormal lipid profiles.
Nine patients were positive for the -175GfT promoter polymorphism, but no
association with hypertension could be demonstrated. There was a positive
correlation between body mass index (BMI) and the deelopment of pre-eclampsia
(p=0.0002), although this association was not observed in subjects with the T-allele
at nucleotide position -175 (BMI> 25 in 7/9 cases).
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Conclusion
This study has found no evidence that LDLR gene mutations may contribute to
elevated lipid levels in pre-eclampsia. Further investigation is warranted to explain
the apparent absence of pre-eclampsia in subjects with a relatively high body mass
index in the presence of mutation -175GfT.
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Introduction
Fatty acids are an important precursor for prostaglandins and membrane lipids and
are also a critical source of metabolic energy. Unsaturated non-esterified fatty acids
(free fatty acids, FFA) are intrinsically toxic and have the ability to form free radicals.
The concentration of these fatty acids is elevated months before the development of
pre-eclampsia [Lorentzen et ai, 1995]. There is also a significant association between
first trimester total serum cholesterol and the risk of pre-eclampsia [Van den Elzen et
ai, 1996]. This dyslipidaemia of pre-eclampsia is an exaggerated response of the
typical increase in circulating free fatty acids that take place in the late second
trimester during normal pregnancy.
The fasting serum triglyceride concentration also increases in pre-eclampsia and
levels of triglycerides and free fatty acids decrease within 48 hours postpartum
[Hubel et ai, 1996]. It is postulated that the link between elevated lipids and the
endothelial dysfunction of pre-eclampsia could be oxidative stress [Gratacos, 2000].
Free radical reaction products, such as malondialdehyde, a metabolite of lipid
peroxidase, is positively correlatedwith pre-eclampsia [Hubel et ai, 1996].
Postmenopausal women with a history of recurrent hypertension during their
pregnancies have significantly increased diastolic blood pressure and atherogenic
profiles when compared to matched controls without a prior history of hypertension in
pregnancy [Hubel et ai, 2000]. Also, the risk of dying from ischemic heart disease in
later life is increased in women who have had hypertensive disease in pregnancy
(Relative Risk 2.61, 95% Confidence Interval 1.11- 6.12) [Jonsdottir et ai, 1995]. It is
likely that a combination of genetic predisposition and environmental factors for
atherosclerosis in later life is unmasked earlier in life, by pregnancy, as pre-
eclampsia. Further evidence for this potential metabolic syndrome is an elevated
body mass index (BMI; kg/m2) in women with pre-eclampsia, regardless of parity,
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before, during and after pregnancy; compared with women with normotensive
pregnancies [Barden et al, 1999].
There is very little data available on the reason for the exaggerated response of
plasma lipids during and preceding pre-eclampsia. Mutations in the low-density
lipoprotein receptor (LDLR) gene cause familial hypercholesterolaemia (FH). This
disease is common in the South African population and founder mutations in the
LDLR gene contribute significantly to the hypercholesterolaemia phenotype in the
indigenous South African Afrikaner and mixed-ancestry populations [Loubser et ai,
1999]. There is also a high incidence of pre-eclampsia in this same population.
African women are also more prone to hyperlipidaemia during normal pregnancy
[Ahaneku et al, 1996].
Three founder-related mutations in exons 4 and 9 of the LDLR gene (D206E, V408M
and D154N) account for most cases of FH in the Afrikaner [Kotze et al, 1989; 1991,
Leitersdorf et al, 1989] and Coloured population of South Africa [Loubser et al, 1999].
A six basepair deletion in exon 2 of the LDLR gene predominates in FH Africans
[Thiart et ai, 2000]. A recently described -175GfT variant in the footprinting 2 (FP2)
cis-acting regulatory element of the LDLR gene may play an important role in
hypertension by virtue of a possible effect on calcium metabolism [Scholtz et ai,
submitted]. Two other common mutations in exon 4, a3 bp deletion (651 del GGT)
[Meiner et al, 1991] and an A to G substitution at position 662 (D20OG)can also be
detected using the same primer set as for the other mutations in exon 4 [Hobbs et al,
1992]. The role of these seven mutations has not been examined in the
pathophysiology of pre-eclampsia.
Our hypothesis is that common mutations in the LDLR gene implicated in
dyslipidaemia and endothelial damage may also be associated with pre-eclampsia.
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The purpose of this study was to obtain a fasting lipogram at booking and to perform
mutation analysis of the seven common mutations for correlation with the eventual
pregnancy outcome.
Materials and methods
Patient selection
One hundred and thirty seven patients were recruited at the time of their first
antenatal visit at a tertiary institution in this non-experimental cohort analytical study.
Most patients book at this clinic because of prior pregnancy complications, especially
hypertensive conditions or recurrent miscarriages. However, the clinic also serves as
a primary care facility for the immediate community and a fair number of low risk
patients visit the clinic.
Eleven patients were excluded from the study due to failure to obtain required
genotypic and biochemical information. The study was approved by the Ethics
Committee of the University of Stellenbosch as part of the ongoing Genetic Aspects
of Pre-eclampsia investigation (GAP study) and all patients provided informed
consent.
At the time of booking, a blood sample for DNA extraction was obtained (in 1/10
volume ethylenediaminetetraacetic acid (EDTA» and frozen at -78°C until DNA
extraction could be performed. The patients were asked to retum the following
moming for a fasting lipogram, unless they were fasting at the time of booking. They
were then followed up routinely and clinical information was obtained from the
clinician's notes following delivery. DNA extraction and mutation analysis were only
performed after delivery so as not to influence the management by the attending
physician. Results were only correlated with the clinical outcome after all information
was collected.
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Serum lipograms were performed at a routine chemical pathology laboratory using
standard protocols. Atherogenic lipid profiles were defined as levels above the 80th
percentile for gender and age [Rossouwet ai, 1985]. This cut-off point should
correctly identify more than 90% of cases of FH. Pre-eclampsia was defined by the
criteria detennined by the International Society for Hypertension in pregnancy. This is
a blood pressure of 140/90 mmHg on two occasions, at least four hours apart, arising
for the first time after 20 weeks of gestation, coupled with significant proteinuria (300
mgll in a 24-hour urine collection or 2+ on diagnostic urine sticks) [Davey and
MacGillivray, 1988].
DNA extraction
DNA extraction was performed using an adaptation of the salting out procedure as
originally described by Miller et al (1988). EDTA stored whole blood (5 ml) was lysed
with buffer and the cell Iysates incubated overnight at 55 °C with nucleic lysis buffer
and proteinase K. The next morning, 1 ml of saturated 6M sodium chloride solution
was added and the solution centrifuged. The DNA containing supernatant was
carefully decanted into a clean polypropylene tube and 20-30 ml of ice-cold absolute
ethanol added to precipitate the DNA. The precipitated DNA was briefly washed in
70% ethanol prior to airdrying and subsequently diluted sterile distilled water for use
in polymerase chain reactions (PCR).
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LDLR mutation analysis
LDLR promoter amplification
PCR reaction mix (per reaction)
Forward primer: 5' aggcagagaggacaatggc 3' 0.55 fl.1
Reverse primer: 5' cacgacctgctgtgtccaagcttgaaaccc 3' 0.25 fl.1
PCR buffer (1Ox) 5 f.11
Taq polymerase (5U/f.11) 0.15 fl.1
Deoxynucleotides (5mM) 10 f.11
Genomic DNA 1 f.11
Distilled water 33.05 fl.1
Total volume 50fl.1
Thermal cycling was started at 95°C for 1 minute, followed by 10 cycles (95°C for 10
seconds, 60°C for 45 seconds, 72°C for 45 seconds) and another 30 cycles (95°C for
10 seconds, 5aoC for 45 seconds, 72°C for 45 seconds). The resultant DNA fragment
was 430 basepairs in size.
LDLR coding region amplification (exon 4)
PCR reaction mix (per reaction)
Forward primer: 5' cccccagctgtgggcctgcg 3' 0.2 f.11
Reverse primer: 5' cgcccccaccctgccccgcc 3' 0.2 f.11
PCR buffer (10x) 5f.11
Taq polymerase (5U/f.11) 0.1 f.11
Deoxynucleotides (5mM) 10 f.11
Genomic DNA 1 f.11
Distilled water 33.5 f.11
Total volume 50f.11
Thermal cycling started at 95°C for 2 minutes and 30 seconds, followed by 35 cycles
of 94°C for 1 minute, 71°C for 1 minute and 72°C for 2 minutes. The final extension
was done at 72°C for 10 seconds. A DNA fragment of 237 basepairs was generated.
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LDLR coding region amplification (exon 9)
PCR reaction mix (per reaction)
Forward primer: 5' cccctgacctcgctccccgg 3' 0.33 JlI
Reverse primer: 5' gctgcaggcaggggcgacgc 3' 0.2 JlI
PCR buffer (10x) 5JlI
Taq polymerase (5U/JlI) 0.1 JlI
Deoxynucleotides (5mM) 10 JlI
Genomic DNA 1J.L1
Distilled water 33.37JlI
Total volume 50JlI
A denaturation step of the PCR reaction was initiated at 95°C for 1 minute, followed
by 10 cycles (95°C for 5 seconds, 63°C for 30 seconds, 72°C for 30 seconds) and
another 30 cycles (95°C for 5 seconds, 62°C for 30 seconds, 72°C for 30 seconds). A
DNA fragment of 224 basepairs was generated.
Mutation detection by gel electrophoresis
A 10% polyacrylamide gel was used, supplemented with 7.5 % urea for the V408M
mutation analysis and supplemented with 5% glycerol for the combined heteroduplex
and single-strand conformation polymorphism (HEX-SSCP) analysis of mutations
D206E, D154N and the 3 bp deletion (codon 197) [Kotze et al, 1995]. A 10%
polyacrylamide gel supplemented with 7.5% urea was used for the HEX-SSCP
detection of the -175GIT LDLR promoter variant. When a variant in the SSCP was
detected in exon 4, exon 4 PCR products were digested with Msp I restriction
enzyme to identify mutation D200G. Non-denaturing 10% polyacrylamide gel (3%C)
were used to resolve restriction enzyme digested PCR products.
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Results
The demographic characteristics of the study population are listed in Table I. The
pregnancy of 12 (9.5%) patients ended in a miscarriage. Nineteen (15%) developed
pregnancy-induced hypertension and 10 (7.9%) developed pre-eclampsia. Ten
patients (7.9%) had significantly elevated blood lipids (>90th centile). An elevated
body mass index (BMI) at booking was significantly associated with the development
of pregnancy- induced hypertension (p = 0.0002). The median BMI of patients with
normal outcome was 26 and in the hypertensive groups 33.
There was no relationship demonstrated between elevated BMI and abnormal
cholesterol levels (BMI 25 vs. 27). No patient had any of the mutations screened for
in the coding region of the low-density lipoprotein receptor.
In the promoter region, nine patients tested positive for the -175Gff variant. These
patients tended to be heavier (BMI 31), but there was no significant association with
the development of hypertension in pregnancy or with a history of prior hypertension.
Three of these patients (2.4%) had a history of previous abruptio placentae but this
did not differ significantly from the other patients (OR 3.44, 95% Cl 0.41- 33). The
average lipid profile for these patients was normal.
Discussion
This study has found no evidence that mutations in the coding region of the LDLR
gene are implicated in elevated serum lipids in pre-eclampsia. The -175Grr
polymorphism has been associated with elevated diastolic blood pressure in non-
pregnant patients (Scholtz et ai, submitted). In the study cohort described above,
patients with the polymorphism had a higher BMI, which on its own is associated with
the development of pre-eclampsia. However, the incidence of pre-eclampsia did not
differ from the rest of the group. It may be that the vasodilatation of normal
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pregnancy masks the described association or that it may be more important in the
non-pregnant state.
Another possible explanation lies in the induction of LDLR gene transcription by
calcium [Makar et ai, 1994]. This may be the mechanism by which elevated LDL is
associated with hypertension. In normal pregnancy, there is a doubling in the gut
absorption of calcium to supply in the fetal demand. Furthermore, calcium
supplementation in pregnancy leads to an important reduction in both systolic and
diastolic blood pressure and pre-eclampsia [Bucher et ai, 1996]. None of these
patients was on calcium supplementation. This possible confounding factor needs to
be addressed outside of pregnancy.
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Table I
Demographic characteristics of the study population
Age (median) 31 (16-44)
Gravidity 3 (1-10)
Parity (median) 1 (0-7)_
Gestation at booking 16 weeks (16-38)
Race Coloured 86.5% Black 13.5%
Gestation at delivery 38 weeks (28-42)
Birthweight(median) 2981 gram (824-4630)
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Summary
During normal pregnancy, complex alterations in clotting and fibrinolytic factors tip
the scale in favour of coagulation. This is advantageous in the face of blood loss
during delivery. However, disease processes causing thrombosis and infarctions in
the placentae, as with the antiphospholipid syndrome, eventually lead to intra-uterine
growth restriction and the development of pre-eclampsia. By similar analogy,
thrombophilic mutations can contribute to the development of placental vasculopathy.
This has been observed in Caucasian populations with the factor V Leiden and the
A20210G prothrombin mutations, while these mutations are virtually absent in Black
patients. In this study, performed on Coloured and Black patients with pre-eclampsia
in the Westem Cape region of South Africa, the frequency of both mutations was
shown to be very low and does most likely not contribute significantly to the observed
high incidence of placental vasculopathy.
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Introduction
Pre-eclampsia is a condition unique to pregnancy and primarily affects the maternal
and placental vascular endothelium. It is a major cause of both morbidity and
mortality and the perplexing aetiology and pathophysiology have made it one of the
most researched conditions in obstetrics.
During normal pregnancy, there are dramatic changes in the coagulation and
fibrinolytic system. There is deposition of fibrin in the uteroplacental walls and
fibrinolysis is suppressed. There is an increase in levels of clotting factors VII, VIII
and X and a doubling in the levels of fibrinogen. The end result is the well-described
hypercoagulability of pregnancy, protecting the mother against blood loss at delivery,
but also predisposing her to thrombotic complications. Protection against generalised
thrombosis is supplied by naturally-occurring anticoagulants, of which antithrombin III
and the protein C-thrombomodulin-protein S complex are the most important. Protein
C inactivates Factors Vand VIII in conjunction with its cofactors protein Sand
thrombomodulin. Abnormal forms of Factor V, such as those arising from DNA
mutations, resist such inactivation and can lead to thrombosis.
The association between placental infarcts and adverse pregnancy outcome,
especially midtrimester pregnancy loss and the development of pre-eclampsia, is well
described in the antiphospholipid syndrome. Progressive thrombosis and infarcts in
the placenta lead to intra-uterine growth restriction (IUGR), pre-eclampsia and
abruptio placentae. If one accepts this pathogenesis, a logical hypothesis would be
that other forms thrombophilia should also be associated with adverse pregnancy
outcome [Nelson-Piercy, 1999].
One such inherited abnormality, described in 1993, is activated protein C resistance
(APCR) [Dahlback et al, 1993]. Coagulation factor V (FV) acts as cofactor for
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activated Factor X to activate prothrombin in the coagulation cascade. Factor V is
cleaved and inactivated by activated protein C. The human Factor V gene contains
25 exons that range from 72 bp to 2820 bp in length and spans more than 80 kb
[Simioni et al, 1999]. Bertina et al (1994) described a mutation in exon 10 of the
factor V gene (A1691G) which result in the substitution of an arginine with a glycine
residue and abolishes the site of protein C cleavage. This variant was named the FV
Leiden mutation, after the city in which it was discovered.
The relationship between activated protein C resistance and adverse pregnancy
outcome was first reported in 1996 [Rai et al, 1996]. At a specialist recurrent
miscarriage clinic, the prevalence of APCR was significantly higher among women
with a history of second-trimester miscarriage (20%) than a control group (4.3%;
p<0.02). In the same year results of the European Prospective Cohort on
Thrombophilia (EPCOT) were published [Preston et ai, 1996]. The study included
1384 women; of 843 women with thrombophilia, 571 had 1524 pregnancies. In the
control group of 541 women, 395 had 1019 pregnancies. The highest odds ratio for
stillbirth was in women with combined defects of coagulation (FV Leiden mutation,
antithrombin III deficiency and protein C and S deficiencies) (OR 14.3, 95% Cl 2.4-
86).
The association between FV Leiden mutation and pre-eclampsia was first reported in
1995 in a small patient cohort with severe early-onset pre-eclampsia [Dekker et ai,
1995]. In a larger study of 158 women with severe pre-eclampsia, the incidence of
FV Leiden mutation was 8.9% and in a control group 4.2% (l 4.686, p=0.03). All
patients were heterozygous for the mutation [Dizon-Townson et ai, 1996]. Since then,
several reports from different parts of the world have confirmed or contradicted this
association (Table I).
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In 1996, a guanine to adenine transition at position 20210 in the 3' untranslated
region of the prothrombin gene, was described [Poort et ai, 1996]. This mutation
(G20210A) was associated with elevated plasma prothrombin levels and an
increased risk of venous thrombosis. An independent association with pre-eclampsia
was recently reported in Italy (OR 3.31; 95% Cl 1.12-6.56) [Grandone et al, 1999]. In
another study of 110 women with serious pregnancy complications (abruptio
placentae, severe pre-eclampsia, IUGR) the incidence of the A20210G mutation in
the prothrombin gene was 10% compared to 3% in a control group (p<0.03)
[Kupferminc et al, 1999].
The frequency of factor V Leiden mutation in patients with venous thrombosis in the
Western Cape is 26% in Caucasians, 8% in Coloured and absent in Black African
patients [Rubinstein et ai, 2000], while the frequency of the prothrombin mutation is
unknown in this population. With the broad scope in incidence between different
populations and with the high incidence of placental vasculopathy in the study
population, we investigated the contribution of these two mutations to pre-eclampsia
in the pregnant population of the Western Cape province in South Africa.
Patients, material and methods
Patients and controls
All the patients involved in this study were consecutively enrolled between March
1999 and December 2000. The control group (n=50) consists of 50 multigravidae
who had pregnancies uncomplicated by any of the hypertensive conditions (Coloured
n = 40, Black n = 10). They were selected after term delivery in the labour ward at
Tygerberg Hospital. Patients with infants with a birth weight below the tenth centile
for gestation were excluded to prevent inclusion of possible undiagnosed placental
vasculopathy.
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The study group (n=300) consisted of 150 primigravidae and 150 multigravidae with
severe pre-eclampsia or pregnancy-induced hypertension (Coloured n = 222; Black n
= 78). Hypertension in pregnancy is defined by the criteria determined by the
International Society for Hypertension in pregnancy. This is a blood pressure
measurement of 140/90 mmHg or more on two occasions, at least four hours apart,
arising for the first time after 20 weeks of gestation. If coupled with significant
proteinuria (300 mgll in a 24-hour urine collection or 2+ on diagnostic urine sticks) the
diagnosis of pre-eclampsia was made [Davey and MacGillivray, 1988].
The demographic characteristics of the patients in the different groups are listed in
Table II.
Informed consent for the study was obtained from all patients and the Ethics
Committee of the University of Stellenbosch approved the study (project number
99/025).
Blood collection and DNA extraction
Blood samples for DNA extraction were obtained the morning following delivery from
a clean venepuncture in the cubital fossa. Five millilitres of blood were collected in a
tube containing EDTA (1/10 volume 0.5M sodium EDTA) and samples were frozen at
-78°C until DNA extraction could be performed. DNA extraction was subsequently
performed using an adaptation of the original salting out procedure as originally
described by Miller et al (1988).
peR protocol
A multiplex allele specific amplification polymerase chain reaction (ASA PCR) was
performed using primers described by Hezard et al (1998).
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PCR reaction mix
A reaction mix (total volume 50 f.ll) consisting of the following was set up for each
microliter of template DNA: Taq polymerase buffer (10x), 5mM deoxynucelotide mix,
1 U Taq polymerase (5U/f.l1),distilled water and a combination of prothrombin reverse
primer (wild-type), prothrombin forward primer (consensus) and factor V forward
primer (wild-type) and reverse primer (consensus) for the detection of the wild-type
allele. The primer concentration was 10pmol/f.lI for all the primers used. "
Primers prothrombin reverse (mutant) and forward (consensus) and factor V forward
(mutant) and reverse (consensus) were utilised for the detection of the mutant
prothrombin and factor V Leiden alleles.
PCR conditions
Thermal cycling was performed at 95°C for 1 minute, followed by 30 cycles of 95°C,
1 minute; 56°C, 1 minute; 72°C, 1 minute followed by a final extension step of 72°C
for 5 minutes. PCR products were resolved on a 1% Agarase gel, stained with
ethidium bromide and visualised under ultraviolet light.
Results
Five patients (1.6%) were positive (heterozygous) for the Factor V Leiden mutation
and two (0.6%) tested positive (heterozygous) for the A20210G prothrombin gene
mutation (Table III). The five patients in the factor V group all belonged to the
Coloured population group (5/222 = 2.2%); none of the Black. patients tested positive.
Both patients with the prothrombin gene mutation were primigravidae with early
onset, severe pre-eclampsia (Coloured 1/222, 0.4%; Black. 1/74,1.3%).
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No mutation could be detected in any of the relatively healthy patients in the control
group. All mutation positive patients had an uneventful postpartum course and none
developed any sign of thrombotic complications.
Conclusion
The public health relevance of mutations associated with disease would largely
depend on the mutation frequency in a specific population. The incidence of these
thrombophilic mutations is extremely rare in the population studied and is probably
not a significant contributing factor to the development of pre-eclampsia. Antenatal
screening for inherited thrombophilia in these patients (South African Blacks and
Coloureds) is not warranted. It remains to be seen whether these mutations are more
common in South African Caucasians with pre-eclampsia. The frequency of these
mutations in the general South African population has not been determined yet.
Molecular studies of disease may produce significant findings in only a small number
of patients, but once the full genetic tapestry is unravelled, it may reveal more about
the mechanism of a disease. The apparently small contribution of inherited
thrombophilia to placental infarctions and pre-eclampsia in the South African
Coloured and Black population suggests that there may be other as yet unknown
underlying hypercoagulability factors that play a role in these conditions. It may also
imply that the real cause of placental vasculopathy lies elsewhere, and that a
tendency to increased clotting only unmasks this condition earlier in susceptible
patients.
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Table I
The distribution of FV leiden mutation and relationship to adverse pregnancy
outcome
Countryl region Condition n Incidence Reference
Israel Recurrent fetal 39 48% Brenner et al,
loss 1997
Israel Poor obstetric 7 100% Rotmensch et
history al,1997
Hungary Severe pre- pregnant = 71 7% Nagy et al, 1998
eclampsia non-pregnant = 58 5.2%
pre-eclampsia = 69 18.8%
HELLP 21 19% Krauss et al,
1998
New South Wales Severe pre- pregnant = 150 0.07% Mimuro et al,
eclampsia pre-eclampsia = 50 8% 1998
Pre-eclampsia 116 FV positive 25% Hastings et al,
women 1998
Italy Pre-eclampsia controls = 4 1.8% Grandone et al,
. pre-eclampsia = 11 7.9% 1999
East Anglia (UK) Pre-eclampsia control = 200 5.3% O'Shaughnessy
pre-eclampsia = 283 5.5% et al, 1999
New York IUGR General population 7.9% Wisotzkey JD et
IUGR = 35 0% al,1999
Israel Pre-eclampsia 110 20% Kupferminc et
al,1999
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Table II
Demographic characteristics of the study population
Control group Study group p value
n 50 300
Gravidity 3 (2-8) 2 (1-8)
Parity 2 (1-7) 2 (1-8)
Race: % Coloured 90% 74%
Race: % Black 10% 26%
Gestational age: delivery 39 (37-44) 33 (20-44)
Birth weight 3256g 2400g p<0.05
(2460g-4576g) (1220g-4498g)
Smoking in pregnancy 40% 19% p<0.05
Systolic blood pressure (mmHg) 120 (100-140) 160 (130-220) p<0.05
Diastolic blood pressure (mmHg) 80 (60-90) 105 (80-105) p<0.05
Age 29 (18-43) 25 (14-46)
All values are the median. The range is given in parenthesis
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Table III
Patient characteristics
Mutation Complication
Prothrombin Severe Pre-eclampsia
1 0 Prothrombin Severe Pre-eclampsia
36 Coloured 4 2 Factor V Pre-eclampsia No
26 Coloured 3 2 Factor V Pre-eclampsia Yes
30 Coloured 2 1 Factor V Abruptio placentae No
20 Coloured 1 0 Factor V Abruptio placentae No
28 Coloured 1 0 Factor V Hypertension No
G = gravidity
P = parity
Prothrombin = A20210G Prothrombin mutation
Factor V = Factor V Leiden mutation
Smoke = smoking during pregnancy
Hypertension = pregnancy-induced hypertension
32 1722
36 3794
40 3260
30 1394
34 1250
41 2306
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Abstract
Objective
To investigate the role of hyperhomocysteinaemia and two common mutations
(C677T and A1298C) in the methylenetetrahydrofolate reductase (MTHFR) gene in
the pathophysiology of pre-eclampsia.
Design
One hundred and ten normotensive and 350 women with pregnancies complicated
by pre-eclampsia, hypertension or abruptio placentae participated in the study.
Methods
Fasting levels of homocystein were obtained after delivery. Genotyping for the two
mutations was performed on genomic DNA with polymerase chain reaction
amplification, restriction enzyme analysis and gel electrophoresis.
Results
The mutant T allele of the C677T mutation was significantly associated with
hyperhomocysteinaemia (p = 0.0095; OR 2.27, 95% Cl 1.15-4.46). There were
significantly more Black patients with abnormal homocystein levels (p = 0.0033).
Most of the patients (44%) with abnormally elevated homocystein levels presented
with early-onset severe pre-eclampsia (p = 0.0396). The allele frequency of the
mutated C allele of mutation A1298C was significantly associated with diastolic blood
pressure (OR 1.90, 95% CI1.20-3.03; P = 0.0055).
Conclusion
The high incidence of homozygosity for A1298C, a mutation not usually or apparently
associated with homocysteinaemia, in pre-eclampsia, and the elevated homocystein
levels in Black patients lacking the mutation screened suggests other possible
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contributions of these mutations to the pathophysiology of pre-eclampsia in this
patient cohort.
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Introduction
Hyperhomocysteinaemia can occur in two forms- the severe form, usually referred to
as homocysteinuria, is autosomal recessively inherited and results from deficiencies
in the cystathione-B synthetase or methylenetetrahydrofolate reductase (MTHFR)
enzymes. The mild form is a risk factor for vascular disease, but does not cause
overt disease [Boushey et al, 1995].
The most common genetic defect that results in mild hyperhomocysteinaemia is a
substitution in the methylenetetrahydrofolate reductase (MTHFR) enzyme, resulting
in decreased plasma folate levels and impaired homocystein remethylation [Rozen,
1997]. The homocystein levels in women with pre-eclampsia are significantly higher
than in nulliparas without pre-eclampsia [Rajkovic et ai, 1997].
Hyperhomocysteinaemia is also associated with placental infarctions, a finding
common in pre-eclampsia [Goddijn-Wessels et ai, 1996].
The human MTHFR locus was mapped to chromosome 1p36.3 by in-situ
hybridisation [Goyette et ai, 1994]. DNA screening of the MTHFR gene, using the
single-strand conformation polymorphism (SSCP) method for mutation detection,
resulted in the identification of a C to T substitution at basepair 677. This resulted in
the substitution of a valine codon for an alanine residue. Although defective, the
enzyme is still functional. It has decreased stability and is a plausible candidate for
moderate hyperhomocysteinaemia and arteriosclerotic disease. Homozygous mutant
individuals have significantly increased plasma homocystein levels [Ma et ai, 1996].
A second mutation in the MTHFR gene (A1298C), subsequently identified, was
reported to occur with a high carrier frequency in the general population [Weissberg
et ai, 1998]. This mutation is also associated with decreased enzyme activity, but an
isolated mutation (heterozygous state) does not result in hyperhomocysteinaemia.
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Combined heterozygosity for both C677T and A1298C mutations does lead to
hyperhomocysteinaemia [Van der Put et al, 1998] and also appears to be associated
with abruptio placentae [Gebhardt et al, in press].
There is a considerable population specificity of allele frequencies. The frequency of
the C677T mutation in the normal population varies from 16.3% in Italy, to 11%
(Japan), 5.4% (Holland) and 0% (Black Americans) [Fletcher et al, 1998].
A significantly higher frequency of the C677T mutation in patients with pre-eclampsia
has been reported in several different populations [Grandone et ai, 1997; Nagy et ai,
1998; Grandone et al, 1999; Kupferminc et al, 1999]. The role of this mutation in the
development of pre-eclampsia is uncertain, as in other populations no relationship
between pre-eclampsia and C677T mutation could be demonstrated. These include
patient cohorts from East Anglia [O'Shaughnessy et ai, 1999], Japan [Kobashi et ai,
2000], South African Blacks [Chikosi et ai, 1999] and Australia [Kaiser et ai, 2000].
The aim of this study was to determine the frequency of these two mutations in the
predominantly Coloured (mixed ancestry) population of the Western Cape and to
correlate this with biochemical hyperhomocysteinaemia and the development of pre-
eclampsia. The Coloured population of South Africa originated in the sixteenth
century after union between European males and females of two indigenous
populations, the Khoi and the San [Loubser et ai, 1999].
Materials and methods
The control group (n=llO) comprised patients with pregnancies uncomplicated by
any hypertensive condition (in the index pregnancy or any previous pregnancy).
Patients with a birth weight below the tenth percentile for gestational age were
excluded to prevent inclusion of possible undiagnosed placental vasculopathy. The
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study group (n=350) consisted of 100 successive patients with early-onset severe
pre-eclampsia «34 weeks gestation, group A), 100 successive patients with late-
onset pre-eclampsia (>34 weeks, group B), 100 individuals with pregnancy-induced
hypertension (group C) and 50 patients who developed abruptio placentae (Group
D). More than 83% of patients were taking iron and folate supplementation regularly
through their pregnancy.
The hospital is one of two tertiary referral units for the Western Cape Province of
South Africa. The catchment population comprises mainly Coloured and Black
individuals; in 1999 the racial distribution of all deliveries included Coloured 82.8%;
Black 15.6% and Caucasian 1.6%. Participating patients were recruited following
delivery. Blood was obtained the morning following a fasting period to determine
homocystein levels. A clean venepuncture was performed and two tubes of 5 ml
each EDTA blood were collected; one was centrifuged and the plasma removed for
homocystein determination and the other was stored at -78°C for DNA extraction.
All patients participated in an interviewer-administered questionnaire and clinical
details were obtained form the clinician notes. All patients provided written informed
consent and the ethical committee of the University of Stellenbosch approved the
study.
Hypertension in pregnancy is defined by the criteria determined by the International
Society for Hypertension in pregnancy. This is a blood pressure measurement of
140/90 mmHg or more on two occasions, at least four hours apart, arising for the first
time after 20 weeks of gestation. If coupled with significant proteinuria (300 mgll in a
24-hour urine collection or 2+ on diagnostic urine sticks) a diagnosis of pre-eclampsia
was made [Davey and MacGillivray, 1988]. Homocystein levels were determined in a
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chemical pathology laboratory using the method described by Ubbink and co-workers
[1991].
DNA extraction
DNA extraction was performed on whole EDTA-stored blood using an adaptation of
the salting out procedure as originally described by Miller [Miller et ai, 1988]. EDTA
stored whole blood (5 ml) was lysed with buffer and the cell Iysates incubated
overnight at 55°C with nucleic lysis buffer and proteinase K. The following morning,
1 ml of saturated 6M sodium chloride solution was added and the solution
centrifuged. The DNA-containing supernatant was carefully decanted into a clean
polypropylene tube and 20-30 ml of ice-cold absolute ethanol was added to
precipitate the DNA. Precipitated DNA was subsequently briefly washed in 70%
ethanol prior to airdrying and dilution in sterile distilled water.
Mutation detection
MTHFR C677T mutation
This genotyping was performed by polymerase chain reaction (PCR) amplification
and subsequently Hinf I restriction enzyme analysis as originally described by Frosst
et al (1995).
Primers sequences:
Forward: 5' tgaaggagaaggtgtctgcggga 3'
Reverse: 5' aggacggtgcggtgagagtg 3'
Each PCR reaction was performed in a 50 III reaction mix containing 0.8 III (10
pmolll) of each primer, 4 !li mix of the four deoxynucleotide triphosphates (5 mM), 5
III of PCR 10x buffer, 1 III of Taq polymerase (5U/IlI) and 1 III of genomic DNA as
template. Thermal cycling was started at 95°C for 1 minute, followed by 10 cycles
(95°C, 10 seconds; 60°C' 45 seconds; 72°C, 45 seconds) and a further 20 cycles
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(95°C, 10 seconds; 57°C, 45 seconds; 72°C, 45 seconds) and a final extension step
for 1 minute at 72°C. This resulted in the generation of a DNA fragment of 198
basepairs (bp).
The C to T substitution at nucleotide position 677 creates a Hint I recognition site for
enzymatic cleavage. Restriction was performed on 10 JlI of amplified template in a
water bath at 37°C for at least four hours. Bovine serum albumin (10 mg/ml) was
added to enhance the activity of the restriction enzyme. The resulting fragments were
resolved by polyacrylamide gel electrophoresis and ultraviolet illumination. A 198 bp
fragment is cut into 175 bp and 23 bp fragments if the recognition site, and hence the
mutation is present.
MTHFR A1298C mutation
Genotyping was performed by PCR amplification and subsequently Mbo II enzyme
restriction. Primer sequences:
Forward primer 5' atgtggggggaggagctgac 3'
Reverse primer 5' gtctcccaacttacccttctccc 3'
The PCR reaction was performed in a 50 JlI reaction mix containing 1.5 JlI (10 pmolll)
of each primer,S J.1I mix of the four deoxynucleotide triphosphates (5mM), 5JlI of PCR
10x buffer, 1JlI of Taq polymerase (5U/JlI) and 1 JlI of genomic DNA as template.
Thermal cycling was started at 94°C for 1 minute 30 seconds, followed by 30 cycles
(94°C, 30 seconds; 55°C, 45 seconds; 72°C, 1 minute) and a final extension step for
3 minutes at 72°C. The resulting DNA fragment is 241 bp in size.
The A to C substitution of the A 1298C MTHFR mutation abolishes a cleavage site for
Mbo II in the wild type genome. PCR amplified products were digested overnight at
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37°C with Mbo II restriction enzyme and the resulting fragments separated and
analysed with polyacrylamide gel electrophoresis. The wild-type fragment is usually
cut into fragments of 204 and 37 bp respectively.
Results
From the patient questionnaires, it was apparent that there were significantly more
smokers in the abruptio group (D) and in the control group compared with the
hypertensive groups combined (p = 0.0012). From questions regarding family history,
there was also evidence of a significant familial relationship of hypertension during
pregnancy between mothers and daughters. Only 2% of control indiviuals
(uncomplicated pregnancy) had mothers who smoked in their (the mothers')
pregnancy, compared with 10-24% in the other groups with the exception of the
abruptio group (2%) (p = 0.0029).
The distribution of the mutated T allele of the C677T mutation was shown to be
evenly spread in all groups: control group (wild-type CIC 77%, heterozygous state
CIT 21%, homozygous state TIT 2%), groups A and B (CIC 80%, CIT 20%), group C
(CIC 88%, CIT 10%, TIT 2%) and abruptio group (C/C80%, CIT 18%, TIT 2%). Only
three patients were homozygous (TIT) for the C677T mutant allele of whom one was
in the control group.
There were four (3.6%) patients homozygous for the mutant CIC allele of mutation
A1298C in the control group and 37 (10.6%) in the combined patient groups (p =
0.0080; OR 4.18; 95% Cl 1.37-14.26). The mutant allele CIC status was evenly
spread within the patient groups (12 in group A, p = 0.0402; 10 in group B, p =
0.0357; 12 in group C, p = 0.0114; and 3 in group D (p = 0.315». This represents
evidence for a possible association between homozygosity for mutation A1298C and
hypertension in pregnancy. The allele frequency of the mutated C allele was
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significantly associated with raised diastolic blood pressure (OR 1.90, 95% Cl 1.20-
3.03; P = 0.0055).
The mutant T allele of the C677T locus occurred significantly more frequently in
Coloured than in Black study participants (p = 0.0246; 95% Cl 1.05-4.21). Likewise,
the mutant C allele of the A 1298C locus also occurred more frequently in Coloured
participants (p = 0.0407; OR 1.80, 95% Cl 1.14-2.83). However, there were
significantly more Black patients with early-onset severe pre-eclampsia than in any of
the other groups (p = 0.0033). Of the patients with combined heterozygosity for
mutations C677T and A 1298C, only four demonstrated abnormal homocystein levels.
Homocystein levels were determined on samples from 332 patients of whom 68 had
an abnormal elevation in fasting homocystein concentration (>11 umol/l). The mutant
T allele of the C677T locus was significantly associated with hyperhomocysteinaemia
(p = 0.0095; OR 2.27, 95% Cl 1.15-4.46). When all patient groups were combined,
there were significantly more Black patients with abnormal homocystein levels (p =
0.0033). High levels of homocystein could also be associated with a one minute
Apgar score of 5 or less in a significant proportion of patients (p = 0.043) as well as
with intra-uterine death (p = 0.046). Most of the patients with abnormally elevated
homocystein were in the early-onset pre-eclampsia group (44%) (p = 0.0396).
Conclusion
In this study we were unable to determine a direct association between the MTHFR
C677T mutation and the development of pre-eclampsia; however, the C677T
mutation could be associated with hyperhomocysteinaemia and this condition may
contribute to the pathophysiology of pre-eclampsia, with which it is associated. There
was a strong correlation demonstrated between homozygosity for the A 1298C
mutation in the MTHFR gene and the development of hypertensive conditions of
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pregnancy in the cohort studied. Since this mutation on its own is not associated with
clinical elevated homocystein levels, there may be another mechanism by which it
exerts its influence.
One such possibility is interaction or combination with other susceptibility factors.
From this study it does not appear that combined heterozygosity for both MTHFR
mutations can explain the role of the A1298C mutation in hypertensive conditions of
pregnancy, since combined heterozygosity occurred in only 13 patients, including two
of the control group; only four had abnormal homocystein levels.
Plasma folate plays an important role in regulating homocystein, and
hyperhomocysteinaemia is observed primarily when the plasma folate levels are low
or reduced [Jacques et ai, 1996]. The simple intervention of folic acid
supplementation corrects hyperhomocysteinaemia [Nelson-Piercy, 1999]. Since most
(>80%) of the study patients were already on folate supplementation, it may take
more than simple supplementation to correct the molecular defects in this population.
While homocystein levels may appear normal in biochemical testing there may still
be folate deficiency at a cellularl molecular level due to either or both of these
mutations.
There is a significant number of Black patients with early-onset severe pre-eclampsia
with hyperhomocysteinaemia while the allele frequencies of the two MTHFR
mutations were more common in the Coloured population. This suggests enrichment
of a novel mutation in the MTHFR gene in the Black population.
Hypertensive complications of pregnancy tend to recur. It is therefore necessary to
examine the relationship between these mutations and homocystein between
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pregnancies and to investigate the possible contribution of MTHFR mutation status in
the fetus.
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3.5 Analysis of combined heterozygosity for C677T and A1298C MTHFR
mutations in patients with abruptio placentae
In the preliminary work (reported in section 3.2), combined heterozygosity for both
MTHFR mutations (C677T and A1298C) was significantly associated with abruptio
placentae. The control group was randomly selected from group L (lipoprotein study
group). To confirm or dispute this association in a larger, more selected study group,
and to obtain valid statistical analysis, the abruptio placentae group (Group H) was
compared with a control group matched patient by patient with regard to age, race
and gravidity.
The control group was recruited from the uncomplicated pregnancy outcome group
(group A) and from the lipoprotein study group (group L - all patients with
uncomplicated pregnancy outcome). Fifty controls were matched with the abruptio
placentae individuals (n = 50).
Abruptio Control p value
Age (median) 28 28 0.91
Gravidity 2 2 1
Parity 1 1 1
Gestational age at delivery (weeks) 33 39 0.000
Birthweight (median) in gram 1751 3021 0.000
Race (Coloured:Black) 40:10 41:9
There was no difference in the allele frequency of the mutant T allele of the C677T
mutation in the MTHFR gene (p = 0.4455). Likewise, the allele frequency of the
mutant C allele of the A1298C MTHFR mutation did not differ between the two
groups (p = 0.5757). There were three patients with combined heterozygosity for both
Stellenbosch University http://scholar.sun.ac.za
140
mutations in the abruptio placentae group and one in the control group; this
difference did not reach statistical significance. This association will be tested again
once more patients with abruptio placentae are recruited: it is calculated that at least
180 patients are required in each group for valid statistical analysis.
If the two study groups (original report and this study) and two control groups are
analysed together, the association retains its statistical significance.
Abruptio placentae Normal outcome
Combined heterozygosity 7 5
None 61 159
p = 0.0440
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Chapter 4
Conclusion
Pre-eclampsia is likely to be familial in origin and conceivably results from a genetic
interaction between maternal and fetal factors. This suggests that genetic screening
in the future will probably still require an invasive procedure such as chorionic villus
biopsy or amniocentesis. This carries a risk to the pregnancy and until non-invasive
methods for obtaining fetal cells are established, non-invasive measures such as
blood pressure monitoringwill continue to be the most reliable and practical means of
diagnosing this condition [Steer, 1999].
The hypertensive complications of pregnancy tend to recur. In this project, most
homocystein levels were determined after delivery; they may have been abnormally
elevated as part of an acute phase response. It is therefore also necessary to
examine the relationship between mutation status and homocystein level between
pregnancies and to determine the contribution of MTHFR mutation status in the fetus.
It may be that maternal and fetal transmission patterns vary and so influence
outcome.
Any mutation or polymorphism that is maintained in a population may be due to
heterozygous advantage The factor V Leiden mutation may have spread due to
heterozygous advantage; patients with the mutation may have a decreased risk of
post-partum haemorrhage. However, the frequency is still very low in our cohort.
Whether heterozygous advantage is the reason for the high frequency of MTHFR
mutation A1298C remains an open question at this time.
Molecular studies of disease may produce significant findings in only a small
proportion of patients, but once the genetic tapestry is unravelled, it may help fully
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explain the mechanism underlying the disease. The contribution of inherited
thrombophilia to placental infarctions and pre-eclampsia suggests that
hypercoagulability may be a pathophysiological route to abnormal placental
vasculopathy, but only in a small proportion of mainly European patients. There are
likely to be other novel factors underlying hypercoagulability that play a role in
placental vasculopathy. It may also imply that the real cause of placental
vasculopathy lies elsewhere, and that a tendency to increased clotting only unmasks
this condition earlier in susceptible patients.
Future prospects
Future work will include screening for the presence of gene mutations implicated in
endothelial damage and hypertension, this will include the angiotensin receptor gene
and the nitric oxide gene. The significance of fetal mutation status requires further
investigation.
A randomised, controlled trial can be provisionally planned at this stage; the possible
ethical dilemma of giving a placebo instead of folate can be managed by routinely
giving all patients folate and then randomising groups into various extra vitamin
supplementation vs. placebo. More than 80% of patients were taking folate in any
case, and it did not seem to make any difference to the development of pre-
eclampsia and abruptio placentae.
Finally, for a large scale study an adequate, representative control group is needed,
preferably from the representative general population. Planning is currently underway
to obtain cord blood from all deliveries at designated, randomly chosen midwife units
for a single year; this resultant DNA bank of relative healthy, anonymous individuals
can serve as a control group for a variety of molecular studies for years to come.
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PASiëNT INUGTING- EN TOESTEMMINGSVORM
Op soek na genetiese redes vir hipertensie in swangerskap
VERWYSINGSNOMMER:
Navorser/Navorser se verteenwoordiger Getuie
VERKLARING DEUR PASiëNT
Ek, die ondergetekende, van
_________________ (adres)
bevestig dat:
1. Ek uitgenooi is om deel te neem aan bogemelde navorsingsprojek wat deur die Departement van Verloskunde,
afdeling Mensgenetika van die Universiteit van Stellenbosch ondemeem word.
2. Die volgende aan my verduidelik is:
2.1 Doel: Om te kyk of daar 'n genetiese (oorerflike) rede is hoekom sommige swanger vrouens hoë bloeddruk in
swangerskap kry.
2.2 Prosedure: Inligting oor my huidige en vorige swangerskap(pe) sal aan my gevra word. Die inhoud is vertroulik en
alle inligting sal naamloos gehou word. Tydens die geboorteproses gaan twee ekstra buisies naelstringbloed geneem
word vir die bepaling van oorerflike faktore by my baba. Hierdie is addisioneel tot die roetine bloedmonsters wat
geneem word. Verder gaan daar twee buisies bloed by my geneem word vroegoggend, voor ek ontbyt gehad het. Die
res van die bloedmonsters wat by my geneem gaan word, is standaard in die hantering van my swangerskap en
moontlike geassosieerde komplikasies.
3. Ek meegedeel is dat die die inligting wat ingewin word as vertroulik behandel sal word, maar wel aangewend kan
word vir referate op kongresse of ander publikasies.
4. Ek meegedeel is dat ek mag weier om deel te neem aan hierdie projek (asook dat ek enige tyd deelname daaraan
kan staak) en dat sodanige weiering of staking nie op enige manier my huidigeJtoekomstige behandeling by hierdie of
enige ander inrigting sal benadeel nie.
5. Die inligting wat hierbo weergegee is deur aan my in Afrikaans
verduidelik is en dat ek die taal goed magtig is. Ek is 'n geleentheid gegee om vrae te vra en al my vrae is
bevredigend beantwoord.
6. Daar is geen dwang op my geplaas om toe te stem tot my deelname aan die projek nie.
7. Deelname aan die projek geen addisionele koste vir my inhou nie.
Ek stem vrywillig In om deel te neem aan bogemelde projek.
Geteken te, _ op 19 __
Pasiênt se handtekening
of regter duimafdruk
Getuie
VERKLARING DEUR OF NAMENS NAVORSER
Ek, verklaar dat ek:
1. Die inligting vervat in hierdie dokument aan
______________________ verduldelik het;
2. Haar versoek het om vrae aan my te stel indien daar enige iets onduidelik was;
3. Dat hierdie gesprek in Afrikaans plaasgevind het en dat geen tolk gebruik is nie.
Geteken te, op'-- 19__
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PATIENT INFORMATION AND CONSENT FORM
Genetic factors in pre-eclampsia
REFERENCE NUMBER:
Signature or right thumb print witness
DECLARATION BY PATIENT
I, the undersigned, ~:_:_
from, (address)
Confirm that:
1. I was asked to participate in the above-mentioned research project by the department of Obstetrics and
Gynaecology, division Human Genetics at the University of Stellenbosch.
2. The following was explained to me:
2.1 Aim: To see if there are genetic reasons why some pregnant patients develop high blood pressure in pregnancy.
2.2 Procedure: I will be asked to give information on my current and previous pregnancies. All information is
confidential and will be kept anonymous. At birth, two extra tubes of chord blood will be taken in addition to the
routine chord blood taken for blood group determination. This extra blood will be for genetic testing. A further two
tubes of blood will be taken from me the next morning before breakfast. The rest of the blood samples taken from me
will be the routine blood needed for the management of my pregnancy and any possible complications.
3. That all information gathered will be kept confidential, but the information could be used for presentations at a
congress or for publications in medical journals.
4. That I may decline to participate in this project. If I do, this will not influence my current or future management at
this or any other institution.
5. This was explained to me by in English and I am fluent in this
language. I was given ample time to ask any questions and all questions were answered to my full satisfaction.
6. I was not pressurised to participate in this study.
7. There will be no additional costs involved.
Signed at'-- on 19 _
Researcherl representative of researcher witness
DECLARATION BY OR FOR RESEARCHER
I" declare that
1. I explained the information in this document to, _
2. She was given ample time to ask any questions;
3. This conversation was in English and no translator was used.
Signedat on, 19__
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Table XIII
Oligonucleotides for amplification and sequencing the different gene
exons and flanking introns
Gene Name Mutation! Primer name Sequence (5'-3') Produc
variant tsize
Prothrombin G20210A 1A R: -WT cactgggagcattgaggatc
18 - MUT cactgggagcattgaggatt
1C F: - CONSEN tctagaaacagttgcctggc 340bp
MTHFR C677T C677T-F tgaaggagaaggtgtctgcggga 198bp
C677T-R aggacggtgcggtgagagtg
A1298C F atgtggggggaggagctgac
R gtctcccaacttacccttctccc 241bp
FV Leiden G1691A 3A F: -WT cagatccctggacagacg
(ASA3)
38 -MUT cagatccctggacagaca
3C R: - CONSEN tgttatcacactggtgcttaa 174bp
LDL-R prom -175Grr F aggcagagaggacaatggc
R cacgacctgctgtgtccaagcttgaaa 430 bp
LDL-RExon4 D154N F H48 cccccagctgtgggcctgcg
D206E RJ48 cgcccccaccctgccccgcc 237 bp
D200G
651del GGT
LDL-R Exon 9 V408M F H9 cccctgacctcgctccccgg
RJ9 gctgcaggcaggggcgacgc 224bp
Stellenbosch University http://scholar.sun.ac.za
160
LDLR gene mutations
Exon 9 (V408M) amplification
Primer H9 (20pmol) 0.33J.l1
Primer J9 (20pmol) 0.2J.l1
dNTPs (5mM) 10.0 J.l1
10xbuffer 5.0 J.l1
dH20 33.37J.l1
Taq polymerase (5U/J.lI) 0.1 J.l1
DNA 1.0 J.l1
Total: 50 J.l1
PCRprogram
95°C 1 minute
95°C 5 seconds
63°C 30 seconds x10
72°C 30 seconds
95°C 5 seconds
62°C 30 seconds x30
72°C 30 seconds
30°C 10 seconds
Resolve on 10% polyacrylamide gel supplemented with 7.5% urea at 150 Volt
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Exon 4 (D154N, D206E, D200G, 651 del GGT) amplification
Primer H4B (20pmol) 0.21l1
Primer J4B (20pmol) 0.21l1
dNTPs(5mM) 10.01l1
10x Buffer 5.01l1
Taq polymerase (SU/Ill) 0.11l1
dH20 35.31l1
DNA 1.01l1
peR program
95°C 2 minutes 30 seconds
94°C 1 minute
71°C 1 minute 35 cycles
72°C 2 minutes
72°C 10 minutes
30°C 10 seconds
Denature DNA for 5 minutes at 95°C, quench on ice before resolving
Resolve on 10% polyacrylamide gel, supplemented with 5% glycerol, 180 Volt,
overnight
Digest fragments overnight with Mba II for the D154N mutation
Digest fragments overnight with MSP I for the D200G mutation
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MTHFR Mutations
1. A1298C mutation
Amplification
10x Buffer S.OJlI
Forward primer (10pmol/JlI) 0.8,.u
Reverse primer (10pmol/JlI) 0.8JlI
dNTPs (SmM) 4.0JlI
dH20 36.4JlI
Taq polymerase (SU/JlI;1JlI+ SJlIdH20) 2.0JlI
DNA 1.0JlI
PCR Program
94°C 1 minute 30 seconds
94°C 30 seconds
55°C 45 seconds 30 cycles
72°C 1 minute
72°C 3 minutes
20°C 30 seconds
Restriction enzyme analysis (Mbo II)
10x Buffer 2.0JlI
dH20 7.S,.u
Mbo II (12U/JlI) O.SJlI
PCR product 10JlI
Total volume 20 JlI
Resolve on polyacrilamide gel (20JlI+ 5 Jllioading dye) for 2 hours at 250 volt.
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2. C677T mutation
Amplification
10x Buffer 5.0!!1
Forward primer (1Opmolll) 1.5!!1
Reverse primer (10pmoll!!I) 1.5ul
dNTPs (5mM) 5.0!!1
dH20 34.0!!1
Taq polymerase (5U/!!I; 1!!1+ 5!!1dH20) 2.0!!1
DNA 1.0!!1
peR program
95°C 1 minute
95°C 10 seconds
60°C 45 seconds x10
72°C 45 seconds
95°C 10 seconds
57°C 45 seconds x20
72°C 45 seconds
72°C 1 minute
20°C 30 seconds
Restriction enzyme analysis (Hint I)
10x Buffer 2.0 !!I
Bovine Serum Albumin 0.2!!1
Distilled water 6.B!!1
Hinfl (10U/!!I) 1.0!!1
Total volume 20 !!I
Resolve on polyacrilamide gel (20!!1+ 5 !!lloading dye) for 2 hours at 250 volt.
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Multiplex PCR for Factor V Leiden and Prothrombin mutation
Amplification
Normal Mutant
10x Buffer 5.0fJ.1 5.0fJ.1
dNTPs 5.0 fJ.1 5.0 fJ.1
Primers 1a (1Opmol) 1.0 fJ.1
1b 1.0 fJ.1
1c 1.0 fJ.1 1.0 fJ.1
3a (10 pmol) 1.0 fJ.1
3b 1.0 fJ.1
3c 1.0 fJ.1 1.0 fJ.1
Distilled water 33.0 fJ.1 33.0 fJ.1
Taq polymerase (1 fJ.1+5fJ.1dH2O) 2.0 fJ.1 2.0fJ.1
DNA 1.0 fJ.1 1.0 fJ.1
PCRProgram
95°C 1 minute
95°C 1 minute
56°C 1 minute 30 cycles
72°C 1 minute
72°C 5 minutes
30°C 10 seconds
Resolve on 1% Agarose gel
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LDLR GENE (promoter)
peR reaction (50J.11)
100 IJM of each dNTP
10 x PCR buffer
15 pmol of each primer
0.75U Boehringer Mannheim Taq polymerase
Mineral oil (Sigma) overlay
1 !-IIof genomic DNA
peR cycling conditions
95°C for 1 minute
95°C for 10 seconds
10 cycles60°C for 45 seconds
72°C for 45 seconds
95°C for 10 seconds
5aoC for 45 seconds
72°C for 45 seconds
35°C for 5 seconds
30 cycles
HEx-ssep analysis
10 !-IIPCR product and 10J.11gel loading buffer
Heat denaturisation at 95°C for 5 minutes
Quench on ice prior to loading
Combined 10% polyacrylamide /7.5% Urea gel
Overnight electrophoresis at 4°C at 25mA in 1.5 x TBE buffer
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Gel electrophoresis
10% polyacrylamide gel (supplemented with urea)
4.5 g Urea
18 ml5xTBE
27 ml dH20
15 ml Acrylamide (1% C of a 40% stock)
600 J.LIammonium persulphate (APS 10%)
60 J.LI TEMED
10% polyacrylamide gel (supplemented with glycerol)
3 ml Glycerol (5%)
6 ml5xTBE
15 ml Acrylamide (1% C of a 40% stock)
36 ml dH20
800J.L1ammonium persulphate (APS 10%)
80J.LITEMED
Restriction enzyme gel
5 ml Acrylamide (3.4% C of a 40% stock)
4ml5xTBE
10.78 ml dH20
160 J.LIAPS
60J.LITEMED
Agarose gel
1%: 19 Agarose gell100 ml1XTBE buffer
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HEX-SSCP gel
4.5 g Urea
15 ml polyacrylamide (1%C, 40% stock)
18 ml5xTBE
27 ml distilled water
0.8 m110% APS
0.08 ml TEMED
Stock solutions
40% Stock (5%C) for restriction enzyme analysis
76 g Acrylamide
4 g Bisacrylamide
Make up to a total volume of 200 ml with distilled water
40% Stock (1%C); for heteroduplex and SSCP analysis
Acrylamide 39.6g
Bisacrylamide O.4g
Make up to a total volume of 100 ml with distilled water
3.4% C, 40% stock
58.8g Acrylamide
1.2g bis-acrylamide
Fill to 200 ml with distilled water
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Lysis buffer (DNA Extraction)
Ammonium chloride 0.155M
Potassium hydrogen carbonate 0.01 M
EDTA 0.0001M
Adjust pH to 7.4 with concentrated HCI
per 1000ml
8.3 9
1.1 9
0.03 9
Nuclei lysis buffer
Tris-chloride 0.01 M
Sodium chloride 0.4 M
EDTA 0.002 M
Adjust pH to 8.2 with concentrated HCI
per 1000 ml
1.211 9
23.4g
0.6 9
Gel loading buffer
Consists of a 1:1 ratio of a xylene-bromophenol blue mixture - 0.025% bromophenol
blue; 0.025% xylene cyanol; 2.5% ficoll
TBE(5X)
Tris 54 9
Boric Acid 27.5 9
EDTA4.65 9
Make up to 1 litre with distilled water
10% Ammonium persulphate (APS) solution
19APS
10 ml distilled water
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